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ABSTRACT
Economic Burden of Low-value Healthcare on Patients with Localized Prostate Cancer:
Statistical & Machine Learning Approaches
Ryan M. Fiano, MPH

Adults with incident localized prostate cancer represent a large, medically complex population at risk for lowvalue care. Evidence-based guidelines recommend conservative management (CM) for localized prostate
cancer patients with multimorbidity and limited life expectancy, however, 2 in 3 still choose treatment. This
dissertation pursued three Aims to address research gaps related to healthcare practices associated with
significant morbidity and economic burden on older men with incident localized prostate cancer: 1) examine
the leading predictors of low-value healthcare practice of prostate cancer treatment for low-risk prostate
cancer; 2) assess the role of patient‐reported experience with care on high-value prostate cancer management;
and 3) estimate the association of high-value care on non-cancer related healthcare expenditures using
machine learning and statistical approaches. In this study, 2 in 3 adults received low-value prostate cancer
treatment. Multimorbidity and care fragmentation were among the leading predictors of low-value prostate
cancer treatment and contrary to expectations, life expectancy was a weak predictor of treatment receipt. Social
determinants of health were highly ranked predictors of treatment. Higher “timeliness of care” patient reported
experience scores were associated with high-value CM use. Other forms of low-value care before incident
prostate cancer diagnosis were associated with higher non-cancer related healthcare expenditures while highvalue CM was associated with lower costs. In summary, this dissertation highlights the negative effect of
multimorbidity and care fragmentation on overtreatment, high-value care, and cost outcomes. Perceptions of
timely care with healthcare providers and systems have significant impact on high-value CM use among older
men with localized prostate cancer. This dissertation reports strong independent predictive associations of
incremental low-value healthcare use before incident prostate cancer diagnosis to have significant increases on
long-term non-cancer related costs.

DEDICATION
For Haddie and Anderson. May you always have the courage, grit, and patience to pursue your dreams.

iii

ACKNOWLEDGEMENTS
I would like to first thank my mentor, Dr. Usha Sambamoorthi, for her commitment and dedication to
me and this work. Dr. Usha is the most humble and intelligent I have encountered in my life. All her students
recognize her incredible commitment as a mentor, and I am forever grateful for her patience and kindness.
Dr. Gregory Merrick has also made this dissertation possible. Dr. Merrick’s unqualified support,
encouragement, and constructive criticisms serve as a keystone in this work. Thank you, Doc!
To my colleagues Dr. JonDavid Pollock, Dr. Robert Galbreath, and Dr. Wayne Butler for both personal
and professional guidance in this work and my life. You all have influenced my life in innumerable ways, and I
thank you for your example.
I would like to thank my committee members Dr. Traci Lemasters, Dr. Kim Innes, Dr. Malcolm Mattes,
and Dr. Chan Shen for their helpful input and patience throughout the completion of this dissertation.
To my CTSI and PSP classmates for being an overwhelming positive influence on my experience as a
graduate student. I am grateful for the collegial atmosphere only possible among such selfless individuals. I
wish you all the best in your promising futures.
I would like to thank Dr. Mark Olfert, Dr. Paul Chandler, Dr. Julie Lockman, and Dr. Joan Lakoski for
facilitating a great academic experience.
I would like to thank my friends and family for their support. I would like to thank my wife, Amanda,
and two children, Haddie and Anderson, who also endured the stress of completing a graduate degree. To my
parents, Jacqueline and Victor Jr., my brothers Jason, Victor III, and Nicholas for their love, support, and
patience. To my grandparents, Victor Fiano Sr. and Kathryn Fiano, for their unconditional love and jovial
character that have formed the person I am today; you are missed but never forgotten. Together, we all share
this accomplishment.

iv

Table of Contents

List of Tables ......................................................................................................................................................... vii
List of Figures ...................................................................................................................................................... viii
List of Appendices.................................................................................................................................................. ix
List of Abbreviations ................................................................................................................................................x
1 Introduction .......................................................................................................................................................... 1
1.1 Background and Significance ................................................................................................................. 1
1.2 Innovation .................................................................................................................................................. 4
1.3 Specific Aims ............................................................................................................................................. 5
1.4 Approach .................................................................................................................................................... 5
2 Prediction of Low-value Cancer Care among Older Men with Low-Risk Prostate Cancer: A Machine Learning
Approach ................................................................................................................................................................. 8
2.1 Abstract ....................................................................................................................................................... 8
2.2 Introduction .............................................................................................................................................. 9
2.3 Methods .....................................................................................................................................................10
2.4 Results ....................................................................................................................................................... 14
2.5 Discussion ................................................................................................................................................. 15
2.6 Strengths and limitations ..................................................................................................................... 17
2.7 Conclusions ..............................................................................................................................................18
3 Associations of Multimorbidity and Patient-reported Experiences of Care with Conservative Management
among Elderly Patients with Localized Prostate Cancer ...................................................................................... 25
3.1 Abstract ..................................................................................................................................................... 25
3.2 Introduction ............................................................................................................................................ 26
3.3 Methods .................................................................................................................................................... 27
3.4 Results ...................................................................................................................................................... 30
3.5 Discussion................................................................................................................................................ 32
3.6 Strengths and Limitations ................................................................................................................... 34
3.7 Conclusions ............................................................................................................................................. 35
4 Healthcare Expenditures Associated with Low-value Care among Older Men with Incident Localized Prostate
Cancer: Statistical and Machine Learning Approaches ........................................................................................ 42
4.1 Abstract..................................................................................................................................................... 42
4.2 Introduction ............................................................................................................................................ 44
4.3 Methods.................................................................................................................................................... 44
4.4 Results ...................................................................................................................................................... 49
4.5 Discussion................................................................................................................................................ 50
4.6 Strengths and Limitations ................................................................................................................... 53
4.7 Conclusion ............................................................................................................................................... 53
5 Summary and Conclusion .................................................................................................................................. 62
v

5.1 Summary of Findings and Discussion .............................................................................................. 62
5.2 Implications and Suggestions for Future Research ...................................................................... 63
5.3 Strengths and Limitations ................................................................................................................... 66
5.5 Conclusion ............................................................................................................................................... 67
6 References .......................................................................................................................................................... 68
7 Appendices ......................................................................................................................................................... 74

vi

List of Tables
Table 2.1 Patient Characteristics by Treatment Use among Fee-for-Service Medicare Beneficiaries with Incident
Low-risk Prostate Cancer using Linked SEER Cancer Registry, 2009-2014 (n= 13,870) .................................... 19
Continued Table 2.1 Patient Characteristics by Treatment Use among Fee-for-Service Medicare Beneficiaries
with Incident Low-risk Prostate Cancer using Linked SEER Cancer Registry, 2009-2014 (n=13,870) ............. 20
Table 3.1 Patient Characteristics by Conservative Management among Fee-for-Service Medicare Beneficiaries
with Incident Localized Prostate Cancer using Linked SEER Cancer Registry with MCAHPS, 2002-2013
(n=496) ................................................................................................................................................................. 36
Table 3.1 “continued” ............................................................................................................................................ 37
Table 3.2 Multimorbidity and Patient Experiences by Conservative Management among Fee-for-Service
Medicare Beneficiaries with Incident Localized Prostate Cancer using Linked SEER Cancer Registry with
MCAHPS, 2002-2013 ........................................................................................................................................... 38
Table 3.3 Unadjusted (UOR), Adjusted Odds Ratios (AOR) and 95% Confidence Intervals (CI) of
Multimorbidity, Mental Health, Timeliness of Care, Low-risk Prostate Cancer, and Education on Likelihood of
Conservative Management Use among Fee-for-Service Medicare Beneficiaries with Incident Localized Prostate
Cancer using Linked SEER Cancer Registry with MCAHPS, 2002-2013 (N = 496)............................................ 39
Table 4.1 Patient Characteristics by Low-value Care Use among Fee-for-Service Medicare Beneficiaries with
Incident Localized Prostate Cancer using Linked SEER Cancer Registry, 2005-2014 (n=75671) ...................... 55
continued Table 4.1 ............................................................................................................................................... 56
Table 4.2 Healthcare Expenditures by Low-value Care Use among Elderly Fee-for-Service Medicare
Beneficiaries with Incident Localized Prostate Cancer SEER-Medicare, 2005-2014 (n=75671) .........................57
Table 4.3. Healthcare Expenditures by Conservative Management Use among Elderly Fee-for-Service Medicare
Beneficiaries with Incident Localized Prostate Cancer SEER-Medicare, 2005-2014 (n=75671) ........................ 58
Table 4.4 Parameter estimates of PCCI categories from unadjusted and adjusted generalized linear models on
12-24 months healthcare expenditures among elderly Medicare fee-for-service beneficiaries with incident
localized prostate cancer diagnosis using SEER-Medicare data, 2005-2015 (n=75671). .................................... 59

vii

List of Figures
Figure 2.1 Feature Importance of Treatment Prediction among Fee-for-Service Medicare Beneficiaries with
Incident Low-risk Prostate Cancer using SEER Cancer Registry, 2009-2014 (n=13870) .................................... 21
Figure 2.2 Positive and Negative Feature Relationships of Treatment Prediction among Fee-for-Service
Medicare Beneficiaries with Incident Low-risk Prostate Cancer using SEER Cancer Registry, 2009-2014
(n=13870) ............................................................................................................................................................. 22
Figure 2.3 SHAP Partial Dependence Plot of Top 4 Predictive Features of Treatment among Fee-for-Service
Medicare Beneficiaries with Incident Low-risk Prostate Cancer using SEER Cancer Registry, 2009-2014
(n=13870) ............................................................................................................................................................. 23
Figure 2.4 SHAP Partial Density Plot of Life Expectancy and Multimorbidity Predictive Features on Treatment
among Fee-for-Service Medicare Beneficiaries with Incident Low-risk Prostate Cancer using SEER Cancer
Registry, 2009-2014 (n=13870) ........................................................................................................................... 24
Figure 3.1 Cohort Selection and Exclusion ........................................................................................................... 40
Figure 3.2 Adapted Competing Demands Framework .......................................................................................... 41
Figure 4.1 SHAP Feature Importance and Summary Plot of Low-value Care and Conservative Management Use
on Non-Treatment Related Total Healthcare Expenditures among Fee-for-Service Medicare Beneficiaries with
Incident Localized Prostate Cancer using Linked SEER Cancer Registry, 2005-2014 (n=75671) ...................... 60
Figure 4.2 SHAP Partial Density Plots of Selected Features on Non-Treatment Related Total Healthcare
Expenditures among Fee-for-Service Medicare Beneficiaries with Incident Localized Prostate Cancer using
Linked SEER Cancer Registry, 2005-2014 (n=75671) .......................................................................................... 61

viii

List of Appendices
Supplemental Figure 7.0 Aim 1 Inclusion & Exclusion Criteria ........................................................................... 74
Supplemental Figure 7.1 Feature Importance of Treatment Prediction among Fee-for-Service Medicare
Beneficiaries with Incident Low-risk Prostate Cancer using SEER Cancer Registry, 2009-2014 (n=13870) ......75
Appendix 7.2 Unadjusted and Adjusted Odds Ratios and 95% Confidence Intervals (CI) of PCCI, Mental
Health, Timeliness of Care, Low-risk Prostate Cancer, and Education on Conservative Management Use in
among Fee-for-Service Medicare Beneficiaries with Incident Localized Prostate Cancer using Linked SEER
Cancer Registry with MCAHPS, 2002-2013 (N = 496). ....................................................................................... 76
Appendix 7.3 Unadjusted and Adjusted Odds Ratios and 95% Confidence Intervals of PCCI, Multimorbidity,
Mental Health, Timeliness of Care, Low-risk Prostate Cancer, and Education on Conservative Management Use
up to 24 Months after Incident Prostate Cancer among Fee-for-Service Medicare Beneficiaries using Linked
SEER Cancer Registry with MCAHPS, 2002-2013 (N = 496)............................................................................... 77
Appendix 7.4 Prostate cancer treatment codes used within 12 months of prostate cancer diagnosis to Identify
Conservative Management Use ............................................................................................................................ 78
Appendix 7.5 Patient Characteristics by Conservative Management among Fee-for-Service Medicare
Beneficiaries with Incident Localized Prostate Cancer using Linked SEER Cancer Registry, 2005-2014
(n=75671) .............................................................................................................................................................. 79
Appendix 7.6 Low-value Care by Conservative Management Use among Fee-for-Service Medicare Beneficiaries
with Incident Localized Prostate Cancer using Linked SEER Cancer Registry, 2005-2014 (n=75671) ...............81
Supplemental Figure 7.7 ....................................................................................................................................... 83
Appendix 7.8 Aim 1 python codes......................................................................................................................... 84
Appendix 7.8 Aim 3 python codes .......................................................................................................................105

ix

List of Abbreviations
CM
PSA
PREM
LVC
ML
GLM
SDM
SHAP
PDP
PCCI
BBI
BETOS
HCPCS
SEER
MCAHPS
CCI
AOR
UOR
FFS

Conservative Management
Prostate Specific Antigen
Patient Reported Experience Measure(s)
Low Value Care
Machine Learning
Generalized Linear Model
Shared Decision Making
SHapley Additive exPlanations
Partial Density Plot
Prostate Cancer Comorbidity Index
Bice-Boxerman Continuity of care Index
Berenson-Eggers Type of Service codes
Healthcare Common Procedure Coding System
Surveillance Epidemiology, and End Results
Medicare Consumer Assessment of Healthcare Providers and Systems surveys
Charlson Comorbidity Index
Adjusted Odds Ratio
Unadjusted Odds Ratio
Fee-for-Service

x

CHAPTER 1
1 Introduction
1.1 Background and Significance
Epidemiology of localized prostate cancer
Prostate cancer is the most frequently diagnosed malignancy and the 2nd leading cause of cancer death
among men in the United States.(1) In the last several decades, prostate cancer-specific mortality has
decreased significantly and future estimates project robust survivorship growth from 3.3 to 4.5 million by
2026.(2) Wide-spread use of prostate-specific antigen testing has increased detection of malignant and
indolent cancer thus presenting evidence-based management challenges to address prostate cancer specific
mortality of higher-, and avoid overtreatment of lower-, risk disease.(3)
Localized, low-risk prostate cancer
American Joint Commission on Cancer (AJCC) establishes a standard staging system using Tumor,
Node, Metastasis (TNM) classifications for incident prostate cancer diagnoses; primary tumor (T), regional
lymph node involvement (N), and distant metastasis (M) are assessed.(4) Localized prostate cancer, or cancer
that is confined to the prostate, is classified as clinical stage T1 to T2a.(4) Risk stratification, broadly, includes
clinical staging, Prostate Specific Antigen testing, and Gleason Score with 3 main risk groups: low-,
intermediate-, and high- risk prostate cancer.(5) Low-risk prostate cancer is defined as T1 to T2a, Gleason 6,
PSA <10ng/mL, intermediate risk defined as T2b-T2c or Gleason 7 or higher or PSA 10-20 ng/mL, and high
risk defined as T3a or Gleason 8 or higher or PSA > 20 ng/mL.(6)
Treatment selection for localized prostate cancer
Older men with indolent localized prostate cancer and/or limited life expectancy are vulnerable to
adverse effects of overtreatment.(7,8) Overtreatment of localized prostate cancer is associated with negative
health outcomes such as sexual, urinary, and rectal dysfunction including impotence, incontinence, and bowel
irritation.(9–11) To avoid overtreatment morbidities, non-curative conservative management (CM) strategies
have been established as an evidence-based option for adults with localized, low-risk cancer and/or limited life
expectancy.(6,12) Clinical practice guidelines have recommended CM approaches for a decade.(13) More
recently, providing curative treatment of low-risk prostate cancer or higher-risk disease among patients with
1

less than 5 years of life expectancy without discussing CM is considered an indicator of sub-optimal healthcare
quality.(12,14) Thus, the premise of CM is to avoid overtreatment-related adverse effects as localized
malignancies pose little risk of prostate cancer-specific mortality.
The Burden of Low-value Healthcare
For decades, wasteful healthcare spending in the United States has not improved the cost, quality, and
outcomes in comparison to other developed countries. Efforts to identify and address waste, as outlined in the
Institute of Medicines (IOM) seminal work Crossing the Quality Chasm, have promoted a national effort to
develop healthcare quality measurements to promote patient centered care; timely, well-coordinated care to
inform healthcare decisions that reflect the patient’s values.(15) To build on the IOM seminal work, The
National Quality Task Force has redefined effective and patient-centered care as “appropriate, person-centered
care”, thereby recognizing the adverse effects associated with inappropriate healthcare and affirming the need
to understand chronic conditions management within the context of overall well-being.(16)
Low-value care, defined as inappropriate healthcare lacking a net clinical benefit to the patient,
contributes to avoidable morbidities and excessive healthcare costs.(17) Low-value care is prevalent among
elderly patients affecting 1 in 4 Medicare beneficiaries(18) and accounts for $75.7 - $101.2 billion in annual
healthcare costs.(19,20) Use of low-value healthcare services among medically complex patients can lead to
cascades of unnecessary down-stream care, cumulating costs as high as 10 times the original low-value
healthcare service.(21)
To combat and eliminate low-value care, initiatives supported by the American Board of Internal
Medicine Foundation have established the Choosing Wisely campaign to work with other professional societies
to develop lists of low-value screenings, tests, and procedures.(22) Since the establishment of Choosing Wisely
in 2012 study of low-value care has increased substantially. The National Quality Forum outlined opportunities
for increasing requirements to “educate and engage” specific patient populations to reduce low-value care,
while increasing patient-centered, high-value care.(16) However, few studies are oncology focused, with many
examining the overuse of screening (i.e., breast and prostate cancer screening) versus more harmful impacts
associated with overtreatment(23). Significant research gaps exist in the understanding how low-value care
contributes to “down-stream” overtreatment and cost within specific clinical scenarios.
2

Patient-centered care
Patients with incident localized prostate cancer represent a large, medically complex population at risk
of low-value care in the form of overtreatment. Older patients with localized prostate cancer have high rates of
multimorbidity, defined as more than 2 chronic conditions, and often experience an increase in care
fragmentation at diagnosis.(24) Care fragmentation is known to present barriers to shared decision making
and evidence-based recommendations among adults with multimorbidity,(25,26) therefore adults with
multimorbidity may be at increased risk for receiving overtreatment, low-value care, and/or increased downstream survivorship costs.
Shared decision making facilitates patient choice amid the risks and benefits of treatment and nontreatment options. Incident prostate cancer patients are challenged by multimorbidity and care fragmentation
that influence perception of the healthcare system, potentially pushing them to choose an immediate cure(27)
versus managing an additional chronic condition in a fragmented system. Fear of treatment regret, anxiety,
and misunderstanding the risks and benefits of curative treatment within the context of cancer risk grouping
and life expectancy are likely influenced by a patient's perception of care.(27)
The use of patient-reported experience measures can amplify the patient’s perspective of the continuity
of care among primary care and specialty clinicians. Patient reported experiences of care include domains such
as physician communication, timely care, and perceptions of getting needed care and are increasingly used as
quality measures by health plans, medical groups, and physician practices.(28) Positive patient‐reported
experience scores are associated with adherence to medical advice, improved clinical outcomes, and lower
utilization of unnecessary health‐care services.(15,29) Identifying specific measures of patient‐reported
experiences that facilitate CM use among patients with incident localized prostate cancer and multimorbidity is
needed to promote evidence‐based cancer care.(30) For example, in colorectal cancer populations, patient‐
reported experiences with perceived timely care are associated with evidenced‐based follow‐up.(31)
Understanding the relationship between patient‐reported experiences of care on CM use can inform patient‐
centered care approaches by identifying gaps in timely care from the patient’s perspective to improve adoption
of CM use thereby reducing the adverse effects of overtreatment among older patients with multimorbidity and
localized prostate cancer.
3

Economic burden of localized prostate cancer
Many studies have examined comparative costs between different prostate cancer treatment modalities
including CM.(32) CM use is known to reduce short-term treatment-related costs, however, long term costs
associated with overtreatment or low-value care is not known. Use of low-value services prior to incident
prostate cancer may be associated with increased costs throughout survivorship regardless of curative
treatment or CM modalities.
1.2 Innovation
Using recent literature reviews(27,33–37) and healthcare initiative recommendations(16,22), the
research presented in this dissertation addresses significant research gaps as related to healthcare practices
that provide limited clinical benefit, potentially harmful effects, and a significant economic burden on older
men with incident localized prostate cancer. Specifically, we used novel machine learning techniques with
nationally representative samples of older men with localized prostate cancer to answer research questions
with both clinical and population relevance. We used interpretative model-agnostic approaches to understand
the complex machine learning outputs with a focus on understanding predictors of localized prostate cancer
treatment. We also used traditional statistical approaches to understand the impact of patient-reported
outcomes on CM use and non-treatment related costs associated with the use or low-value care prior to
incident localized prostate cancer diagnosis. We identified misalignment between prostate cancer specific,
validated measures of life expectancy and use of guideline recommended care among localized prostate cancer
patients. We also identified the predictive qualities of care fragmentation and use of low-value care on noncancer related healthcare expenditures during survivorship. The innovation of this work addresses the strategic
objectives, research recommendations, and general research gaps as we identify novel factors, such as care
fragmentation, low-value care use, and patient-reported outcomes, on high- and low-value treatment and costs
outcomes among older adults with localized prostate cancer.
To highlight healthcare practices that provide limited clinical benefit, potentially harmful effects, and a
significant economic burden among older men with incident localized prostate cancer, we pursue the following
specific aims:
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1.3 Specific Aims
Aim 1: Use machine learning (ML) to identify leading predictors of cancer treatment within 12 months of
diagnosis among older men with localized, low-risk prostate cancer.
●

Quasi-hypothesis H1: Leading predictors of low-risk prostate cancer treatment will be age,
multimorbidity, care fragmentation, and life expectancy.

Aim 2: Examine the associations of patient‐reported experiences with providers and healthcare systems and
multimorbidity on high-value care (CM use) among older men with localized prostate cancer.
●

H2: Older men with multimorbidity and higher patient experience scores will be more likely to use CM
compared to those without multimorbidity and lower patient experience scores, after adjusting for
patient-, clinician-, and practice ecosystem factors.

Aim 3: Identify leading predictors and estimate the association of high- and low-value care use on non-cancer
related healthcare expenditures among older men with localized prostate cancer.
●

Quasi-hypothesis H3.1: Leading predictors of non-cancer related healthcare expenditures will be age,
life expectancy, low- and high- value care.

●

Quasi-hypothesis H3.2: Independent of treatment or conservative management use, adults using lowvalue care, versus no low-value care, will have higher non-treatment related healthcare costs 12-24
months after a localized prostate cancer diagnosis.

1.4 Approach
Conceptual Framework
Management of preexisting multimorbidity, care fragmentation, and the shared decision making
process associated with choosing treatment or conservative management for incident prostate cancer requires
the use of limited resources (i.e., time to manage chronic conditions and availability of health‐care
professionals and resources). Therefore, in this dissertation we used a competing demands model to
conceptualize factors known to affect localized prostate cancer treatment selection within clinician, patient,
and practice ecosystem domains.(33,38,39)
Data Sources
For aims 1 and 3 we used the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked
5

data files. SEER-Medicare data includes data on all incident prostate cancer cases occurring in 18 regions
throughout the United States. Incident prostate cancer, prostate cancer specific clinical information (i.e.,
Gleason Score and Prostate-specific antigen values), and cancer staging information were derived from the
SEER database. Medicare claims were derived from inpatient, outpatient, and other files linked to SEER.
For aim 2 we used a separate SEER with Medicare Consumer Assessment of Healthcare Providers &
Systems (MCAHPS®) survey linkages. MCAHPS, administered by the CMS, use standardized and validated
questionnaires to collect information on patient‐reported experiences with health‐care providers.(40)
MCAHPS collection methodologies use a weighted probability sampling procedure covering all the 50 US
states, DC, and Puerto Rico, which are then linked to SEER patients.(40,41)
Area Health Resource File (AHRF) files were linked via MEDPAR FIPS state and county codes and used
to calculate urologist densities.(42) Census files were linked to calculate county-level median income and
college education.
We used both statistical and machine learning approaches in this dissertation. All model adjustments
were made with factors known to influence treatment or conservative management selection. We used
frequency and percentages (i.e., Chi-square tests and t-tests) to identify significant group differences by
categorical variables and standard deviations for continuous variables. Generalized linear models (GLM) with
log-link and gamma distribution were used to estimate key independent variable associations with healthcare
cost. In aim 2, multivariable logistic regression was used to estimate the effect of patient-reported experience
measures of care and healthcare providers on conservative management use.
ML methods can determine the most effective and parsimonious model/algorithm through
classification of a binary target (i.e., yes or no dependent variable) via iterative learning. We used the XGBoost
classifier, a decision-tree ensemble machine learning algorithm, to predict prostate cancer treatment or CM use
among patients with low-risk prostate cancer diagnosis.(43)
Traditional statistical approaches use the entire data set and goodness of fit statistics for model
specification.(44) Machine learning techniques utilize a training and test data set to estimate the predictive
accuracy of a model. In ML models, original datasets were split (70%/30%) into training and test data. Next,
predicted labels and probabilities, or a regression form such as log expenditures, were optimized on the
6

training data via hyperparameter tuning using stratified 10-fold cross validation. Hyperparameters can adjust
regularization through iterative tuning runs. Stratified cross validation describes the process of splitting the
training data into identical “folds” that can be used as versions of “unseen” data during testing. Once the
XGBoost algorithm is optimized on training data for accuracy, it is “tested” on the original 30% split. We
assessed predictive performance on the test set using precision, recall, accuracy, and Precision-Recall Receiver
Operating Curve scores for machine learning models in aim 1. In aim 3, XGBoost regressors we used to assess
prediction of log-healthcare costs and performance was assessed using R2 and negative mean squared error.
Shapley Additive exPlanations
To improve machine learning model interpretability, Shapley Additive exPlanations (SHAP) were used
to visually summarize the contributions and associations of the features to the target variable. SHAP values
represent the magnitude of effect from each feature on the model output by conditional expectation when the
feature is “hidden”. Attributed changes induced on the model output are then averaged overall possible feature
orderings in the data set (i.e. coalition) to provide the SHAP value.(45) Feature importance can be calculated
by sorting absolute average SHAP values whereas summary plots sort average SHAP outputs with positive and
negative variations on the x-axis. Partial dependence plots (PDP) average SHAP values for a feature by a
feature’s unit value (for example, average age SHAP values by the feature age in years). Unlike traditional PDP,
SHAP PDP shows dispersion around feature units reflecting the impact of all the other features in the model.
Lastly, PDP interactions display the attribution effect of two features simultaneously. For aim 1 and 3, model
SHAP outputs are log-odds and log-cost, respectively.
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CHAPTER 2
2 Prediction of Low-value Cancer Care among Older Men with Low-Risk Prostate Cancer: A
Machine Learning Approach
2.1 Abstract
Background: Older men with incident prostate cancer are vulnerable to low-value prostate cancer treatment.
Despite evidence-based support for conservative management (i.e., non-treatment), approximately 2 in 3
Medicare beneficiaries receive treatment for low-risk prostate cancer. Adults with multimorbidity who
experience care fragmentation are vulnerable to departures from evidence-based medicine. A comprehensive
analysis of clinical and non-clinical factors, such as life expectancy and care fragmentation, that may drive lowvalue prostate cancer treatment is lacking.
Objective: Use machine learning (ML) to identify leading predictors of cancer treatment within 12 months of
diagnosis among older men with low-risk prostate cancer. Novel predictors included validated prostate-cancer
specific life expectancy and care fragmentation.
Methods: In this retrospective cohort study we linked Surveillance, Epidemiology, and End Results cancer
Registry (SEER), Medicare Claims, Census, and Area Health Resource files and included older men with
incident low-risk prostate cancer from 2009 to 2014 (n=13,870). We used claims data to identify treatment
(Yes/No) in the first 12 months after diagnosis. We used the XGboost algorithm and SHapley Additive
exPlanations (SHAP) to rank feature importance in treatment prediction.
Results: In our study cohort (n=13,870), 66.9% of older adults received cancer treatment. Age,
multimorbidity, care fragmentation, social support, and social determinants were leading predictors of cancer
treatment (Accuracy=0.70, Precision=0.71, Recall=.92, Precision-Recall Area Under the Curve = 0.78).
Relationships of college education, income, and care fragmentation on low-value cancer treatment were
nonlinear and complex. Life expectancy was a weak predictor of prostate cancer treatment.
Conclusion: Our results suggest that non-clinical factors such as social determinants, care fragmentation,
and social support are the most important predictors of treatment among older men diagnosed with low-risk
prostate cancer. Despite a critical role in evidence-based treatment recommendations, life expectancy had
limited impact on treatment selection.
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2.2 Introduction
Localized prostate cancer diagnoses are often indolent, representing a large potential source of lowvalue cancer care. Older men with low-risk prostate cancer and limited life expectancy risk significant urinary,
erectile, and rectal morbidities without the benefit of significant improvement in prostate cancer specific
mortality outcomes.(7,8,10) High-level evidence discourages treatment (3) of individuals with low-risk prostate
cancer with less than 10 years of life expectancy or higher-risk disease with a life expectancy of 5 years or
less.(6) Despite evidence-based support for CM in recent years, treatment for low-risk prostate cancer is highly
prevalent, for example, among Medicare beneficiaries as a majority (58%) still receive treatment as compared
to integrated healthcare network cohorts (20%).(46)
Decision to treat low-risk prostate cancer with radiation, surgery, cryotherapy, chemotherapy, or
hormone therapy requires life expectancy estimation within the context of prostate cancer specific mortality
and death from competing risks. Evidence-based guidelines recommend conservative management for low-risk
prostate cancer and life expectancy of 10 or fewer years.(6) Examining the impact of life expectancy as a
predictor is critical in assessing low-value treatment of low-risk prostate cancer, however, many methods used
in population studies vary considerably and many lack validity in prostate cancer populations.(34)
Multimorbidity is another factor that may influence treatment of low-risk cancer. Over 60% of older
adults with incident prostate have multimorbidity defined 2 or more chronic conditions.(47),(48) Prior studies
with SEER-Medicare data have shown that older men with 3 or more chronic conditions were significantly
more likely to get treated for localized prostate cancer in adjusted multivariable models.(49)
Adults with multimorbidity who experience care fragmentation are vulnerable to departures from
evidence-based medicine and poorer health outcomes.(26) Approximately 50% of adults with multimorbidity
already see 3 or more specialists (50) and increased care fragmentation is associated with diagnosis of incident
prostate cancer.(24) Medically complex adults experiencing care fragmentation prior to diagnosis are likely to
encounter additional barriers to shared-decision making process critical for understanding the risks and
benefits of treatment. Shared decision-making engagement fosters trusting relationships that facilitate
communication of evidence-based recommendations and is associated with reductions in both cancer and noncancer low-value care use.(27,51)
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Supervised ML models are increasingly used to predict healthcare outcomes, quality, and cost
outcomes.(52) However, many studies investigating low-value prostate cancer care use only conventional
statistical approaches. A comprehensive analysis of clinical and non-clinical factors, namely, valid life
expectancy measures, multimorbidity, and care fragmentation, that drive low-value cancer treatment among
adults with incident low-risk prostate cancer is lacking. Supervised ML can be used to identify the leading
predictors and non-linear relationships among medically complex adults with higher probability of
overtreatment.
Therefore, the objective of this study was to identify leading predictors of low-value cancer care among
older men with low-risk prostate cancer using machine learning methods (ML). We used supervised ML
models to identify leading predictors of low-value prostate cancer care by using nationally representative
linked cancer registry-Medicare claims data incorporating a comprehensive list of patient, clinical, and practice
ecosystem features.
2.3 Methods
Study Design
In this retrospective cohort study, the date of incident low-risk prostate cancer diagnosis was used as an
index date and 12 months before diagnosis was used as the baseline period. We defined the treatment for lowrisk prostate cancer (radiation, surgery, chemo- and hormone- therapies) during a period of 12 months after
diagnosis based on validated methods for claims data.(53)
Study population
Older adults (age ≥ 66 years) diagnosed with low-risk prostate cancer during the study period (20092014) were included in the study population. Cancer diagnosis was identified using International Classification
of Diseases for Oncology (ICD-9). Low-risk prostate cancer was defined as American Joint Committee on
Cancer stage T2a or less, Gleason Score ≤ 6, and a PSA test ≤ 10 ng/mL.(6)
Data sources
This study used the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked data files.
SEER-Medicare data includes data on all incident prostate cancer cases occurring in 18 regions throughout the
United States. Incident prostate cancer, prostate cancer specific clinical information (i.e., Gleason Score and
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Prostate-specific antigen values), and cancer staging information were derived from the SEER database.
Patient Medicare claims were derived from inpatient, outpatient, and other files linked to SEER.
Area Health Resource File (AHRF) files were linked via MEDPAR FIPS state and county codes and were
used to calculate urologist densities.(42) Census files were linked to calculate county-level median income and
college education (percentage with college degree).
Study inclusion/exclusion criteria
Adults with low-risk prostate cancer were included in the study if alive and continuously enrolled in
Medicare Parts A and B throughout the baseline and follow-up periods (Appendix Supplemental Figure 7.7).
Adults with missing cancer stage, PSA values, Gleason Scores, and/or those diagnosed with prostate cancer at
autopsy were excluded.
Target variable: Prostate cancer treatment (yes/no)
Prostate cancer treatment was estimated within the first 12 months after diagnosis using a previously
validated, claims-based algorithm and included radiation, surgery, and chemo-, cyro-, and/or hormonetherapy.(53)
Key features
Life expectancy
Prostate cancer comorbidity index (PCCI) is a weighted comorbidity index validated in prostate cancer
patient populations to predict life expectancy.(54) Medical colleges, patient advocacy groups and evidencebased recommend informed decision-making in using conservative management or treatment for men with
low-risk prostate cancer and a life expectancy of greater than 10 years.(6) We calculated PCCI during the
baseline period to create predictive models based on validated life expectancy (10 year or greater life
expectancy; PCCI<8) to reflect evidence-based recommendations.(6,54) Categorical variables at clinically
meaningful cut-offs are presented in Table 2.1 and were also included in sensitivity analyses for interpretative
purposes.
Multimorbidity
The multimorbidity framework developed by the United States Department of Health and Human
Services for guiding programs, practice, and policy guided the selection of chronic conditions as follows:
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arthritis, asthma, coronary artery disease, congestive heart failure, chronic kidney disease, chronic obstructive
pulmonary disease, cardiac arrhythmias, acute myocardial infarction, dementia, diabetes, depression,
hepatitis, hyperlipidemia, hypertension, human immunodeficiency virus, osteoporosis, substance abuse,
schizophrenia, stroke, and anemia.(55) We defined multimorbidity presence of 3 or more chronic conditions.
Care fragmentation
We used a modified version of the Bice-Boxerman continuity of care index to calculate care
fragmentation during the 12 month baseline period.(56,57) The continuity of care index represents the
concentration of visits per patient among health care providers based on visit number, proportion of
encounters to each provider, and total number of visits. The BBI has been used to compare care fragmentation
among cancer survivors and is highly correlated with other measures of care fragmentation.(58) We used
physician specialty codes representing primary care, oncology, and various specialist visit encounters; where n
is the total number of visits, nk is the total number of visits associated with a physician specialty, and k the total
number of physician specialty codes.(59) For example, multiple encounters with a single provider would result
in a score of zero, however, multiple encounters among several health care providers would result in a score
approaching 100. We included primary care, oncology, and many other specialty codes.
Other features
Patient factors included age, race, marital status, county-level median income and education (college
graduation percent). Practice ecosystem included urologist/radiation oncologist density, diagnosis year, SEER
region and Rural groups (Metro, Urban, Rural). All features were calculated in the 12 months before cancer
diagnosis.
Propensity to seek care was also measured by two domains: the number of low-value care services as
well as high-value care. Low-value healthcare services were operationalized using a claims-based algorithm
representing Choosing Wisely campaign recommendations via procedure, diagnosis, hospitalization, and
Berenson-Eggers Type of Service (BETOS) codes using previously published methods.(60–62) We estimated
the feature importance of individual low-value care procedures and summed those with an importance score
greater than zero. We operationalized preventative services based on the National Commission on Prevention
Priorities by the American Academy of Family Physicians as “high-value” care which included lipid and A1c
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screenings, influenza vaccinations, and primary care well visits. We used Healthcare Common Procedure
Coding System (HCPCS) codes to identify preventative care.
All predictors were measured during the 12 month baseline period before incident low-risk prostate
cancer diagnosis.
Statistical Analysis
Chi-square tests and t-tests were used to identify significant group differences in prostate cancer treat
or CM use by categorical variables. All statistical tests were 2-sided with a 5% Type I error rate and completed
in SAS (SAS Institute Inc., Cary, NC, USA. Version 9.4, using Windows 10).
Machine learning
ML methods can determine the most effective and parsimonious model/algorithm through
classification of a binary target (i.e., yes or no dependent variable) via iterative learning. We used the XGBoost
classifier, a decision-tree ensemble machine learning algorithm, to predict prostate cancer treatment or CM use
among patients with low-risk prostate cancer diagnosis.(43)
First, our original dataset was split (70%/30%) into training and test data. Next, predicted labels and
probabilities were optimized on the training data via hyperparameter tuning using repeated stratified 10-fold
cross validation. We used hyperparameter tuning on the training data to optimize performance and avoid overfitting. Hyperparameter tuning parameters codes are available in Appendix Table 7.1.
Final model predictions were evaluated using the original “hold-out” test data. We assessed predictive
performance on the test set using precision, recall, accuracy, and Precision-Recall Receiver Operating Curve
scores. Machine learning analyses were conducted using Python 3.7 with open-source scikit-learn 0.21.3
wrapper interface for XGBoost classifier.
Machine learning interpretation
In the ML model, Shapley Additive exPlanations (SHAP) were used to visually summarize the
contributions and associations of the features to the target variable. SHAP values represent the magnitude of
effect from each feature on the model output by conditional expectation when the feature is “hidden”.
Attributed changes induced on the model output are then averaged overall possible feature orderings in the
data set (i.e. coalition) to provide the SHAP value.(45) Feature importance can be calculated by sorting
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absolute average SHAP values whereas summary plots sort average SHAP outputs with positive and negative
variations on the x-axis. Partial dependence plots (PDP) average SHAP values for a feature by a feature’s unit
value (for example, average age SHAP values by the feature age in years). Unlike traditional PDP, SHAP PDP
shows dispersion around feature units reflecting the impact of all the other features in the model. Lastly, PDP
interactions display the attribution effect of two features simultaneously. All model SHAP outputs are log-odds
and are ranked in decending order.
TreeSHAP was used to generate SHAP values, feature importance, partial dependence plots, and PDP
interactions with Python 3.7 and the SHAP package (0.29.2).
2.4 Results
Descriptive cohort statistics
The study cohort was predominantly non-Hispanic, white (83.3%), marital status of married (69.1%)
with a median age of 72.0 (Mdn=71.1, SD=4.46).
Overall, marital status of married, younger men in the age group 66-74 years, higher income, higher
education level, lower physician quartiles, and adults residing in Northeastern SEER regions more frequently
received treatment for low-risk prostate cancer (Table 2.1). In recent years, (2013 and 2014) mean age was
lower among adults using treatment (M=71.3, SD=4.05) versus no treatment (M=71.7, SD=4.29; p<0.001). Life
expectancy did not significantly differ between adults using treatment versus no treatment, however,
multimorbidity was significantly more frequent among treatment groups (Table 2.1). Preventative care, flu
vaccinations, and primary care visits were significantly more frequent among treatment groups.
Highest ranking predictors
Marital status of married, men in the age group 66-74 years, care fragmentation, median income, and
college education were the top 5 predictive features of low-risk prostate cancer treatment (Figure 2.1). Men
who were married, aged 66-74 years, and experienced care fragmentation were more likely, and those with
higher median income and college education were less likely to receive treatment (Figure 2.1). Northeast SEER
region, diagnostic year 2010, multimorbidity, and west SEER region, more recent diagnostic year (2014 and
2013), were associated with higher and lower SHAP values (log-odds) of treatment prediction, respectively
(Figure 2.1).
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Figure 2.3 shows the complex individual variation among the top 4 predictive features. Overall, SHAP
log-odds decreased with higher median income, however, substatntial individual-level variation in log-odds by
distinct median income values was observed (Figure 2.3 (d)).
Lowest ranking predictors
Life expectancy of 10 or more years (PCCI) and non-cancer low-value care use ranked 22nd and 27th,
respectively in feature importance out of 29 total features (Figure 2.1). SHAP partial density plots illustrate
variation among adults with life expectancies less than 10 years with SHAP log-odds of treatment (Figure 2.4).
Hispanic, black, and white race were 23rd, 24th, and 25th ranked predictors, respectively (Appendix 7.1)
2.5 Discussion
In this first study using ML to predict treatment among older men with low-risk prostate cancer, we
observed that 2 in 3 adults with low-risk prostate cancer received treatment. Other recent SEER-Medicare data
studies also report high (57.9%)(63), while integrated care network studies report low (21%), rates of low-risk
prostate cancer treatment among older men (65+ years). High rates of low-value treatment are concerning as
many men are likely to experience avoidable, negative health related quality of life and higher healthcare costs.
For example, in the Prostate Cancer Intervention vs Observation Trial (PIVOT), a survival benefit to treatment
versus conservative management was not significant after 10 years of follow-up. Treatment of low-risk prostate
cancer confers significant risk of avoidable morbidities(10) and imposes a heavy economic burden of 1.2 billion
dollars in annual cost(64). We speculate that treatment for low-risk prostate cancer may be high as older men
experience adverse mental health effects associated with notification of higher PSA levels, pending biopsy
results, and a prostate cancer diagnosis.(27) However, we observed that diagnosis year was a leading predictor
of treatment, with adults diagnosed in later years (i.e. 2013 and 2014) less likely to receive treatment for lowrisk prostate cancer. Our findings revealing diagnostic year as a highly ranked predictive feature are consistent
with published studies that show treatment of Medicare FFS adults with low-risk prostate cancer have
decreased substantially in the last decade from 86% to 58%(63).
Care fragmentation was among the leading predictors of treatment for low-risk prostate cancer in this
study. Adults experiencing care fragmentation and incident prostate cancer may be inclined to “take care of it”
(27), as managing non-cancer conditions becomes more complex after a prostate cancer diagnosis.(65) In our
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adjusted machine learning models, care fragmentation prior to incident prostate cancer diagnosis was the 3rd
highest in SHAP feature importance, suggesting a strong associative prediction of low-value prostate cancer
treatment. We also observed that older men with multimorbidity were more likely to receive treatment,
consistent with findings of our recently published study indicating that multimorbidity was significantly and
positively associated with likelihood of treatment among older men with localized prostate cancer.(49)
Multimorbidity adds to the complexity to prostate cancer management decisions given that limited physician
and patient resources often compete for management. Specialty healthcare (i.e., urologists and oncologists)
need after an incident prostate cancer diagnosis among older men with multimorbidity is known to increase
care fragmentation.(24) However, although multimorbidity was associated with higher odds of treatment use
in the current study, interactions with care fragmentation were not informative.
Surprisingly, life expectancy was not associated with treatment receipt in this study. Evidence-based
guidelines are based on risk group stratification (i.e., PSA, Gleason Score) and life expectancy. Although clinical
assessment of life expectancy is a critical element to informed decision making for older adults with low-risk
prostate cancer, our study findings suggest that treatment selection might not sufficiently take into
consideration life expectancy.(6) We speculate that greater variation in low-value care use between
organizations, versus between physicians, may reflect practice patterns associated with physician affiliation
and organization management (i.e., compensation, practice guidelines).(66) Findings of other published
studies using alternative methods of life expectancy estimation have been inconsistent, with investigations
showing both positive (67) and negative relationships (68) between comorbidity burden and CM use in
Medicare FFS populations.(49) Taken together, clinical and population differences in comorbidity life
expectancy definitions are likely to account for these mixed findings. We speculate that discrepancies may be
explained by the use of common use of comorbidity indexes that imprecisely measure life expectancy in
prostate cancer populations and likely account for mixed findings.(34,69)
A noteworthy finding of the current study is the apparent role of social determinants (i.e., education
and income) in predicting treatment of low-risk prostate cancer. The relationships were complex among
individuals living in counties with varying levels of income and education. Socio-demographic factors, such as
SEER region, income, college education, and marital status were highly ranked predictors of treatment in this
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and many other (27) investigations. Social determinants of health have also been used to accurately predict
inpatient and emergency room utilization, demonstrating how social determinants can improve predictive
ability of ML models.(70) We found race to be a low-ranking predictor of treatment among low-risk prostate
cancer. Unequal access to care in racial minorities may result in poor management and/or overtreatment of
low-risk prostate cancer as rates of low-risk prostate cancer treatment among racial groups vary between
integrated and fee-for-service cohorts.(71,72) However, we found race to be a low-ranking predictor of
treatment among low-risk prostate cancer in this study.
To our knowledge, this study is the first application of machine learning to estimate predictors of
prostate cancer treatment among adults with low-risk prostate cancer. Unlike traditional statistical
approaches, robust resampling and cross-validation techniques can be used to “train” machine learning
algorithms to accurately predict healthcare utilization. More recently, model agnostic interpretations, such as
SHAP used in this study, enable feature importance ranking and visualizations of individual-level contributions
of patient, clinician, and practice ecosystem factors on target variables. Trade-offs between high performance
and interpretability of complex “black-box” algorithms can be mitigated with SHAP feature importance ranking
and data visualization. Our approach identified the top predictors of low-value treatment of low-risk prostate
cancer and complex non-linear associations among features of high importance. Our results inform clinicians,
payers, and policies makers regarding the predictive associations of features articulated in guideline
recommendations, namely the lack of predictive importance of life expectancy, and the importance of social
determinants, multimorbidity, and care fragmentation.
2.6 Strengths and limitations
Our study has several notable strengths. We used novel machine learning and model agnostic
interpretations (SHAP) to predict and understand treatment use among older men with low-risk prostate
cancer. We included validated measures of prostate cancer-specific life expectancy to identify older men with
low-risk prostate cancer that could benefit from conservative management. Commonly used proxy measures of
comorbidity burden are limited in estimating death risk from prostate cancer. We distinguished between
comorbidity and life expectancy while previous studies have used comorbidity burden as a surrogate of life
expectancy.(34) Using SHAP, we noted both average and individual level variations in CM use which suggests
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many older men could benefit from policies and/or interventions designed to reduce low-value prostate cancer
treatment.
Our study must be interpreted within the context of several limitations. Foremost, the study is a claimsbased, retrospective analysis; therefore, we cannot establish causality and our results are subject to
unobservable variable bias and selection bias of paid Medicare claims. To minimize the proportion of missed
claims we limited analyses to continously enrolled in Medicare (A&B, without HMO) throughout the study
period. Second, our analysis may not be generaliable to commerical insurance beneficiaries as we only
observed Medicare FFS beneficiairies. Third, social determinants of health (i.e., income, education) were not
available at the individual level therefore county level measures were used. We were unable to estimate patient
preference with SEER-Medicare data, and were thus unable to account for adults with longer life expectancies
who prefer curative treatment as conservative management or active surveillance are evidence-based treatment
options.
2.7 Conclusions
Using interpretable machine learning approaches provided evidence for several strong, modifiable
predictors of low-value treatment of low-risk prostate cancer, including care fragmentation and social
determinants of health. Healthcare policies could reduce low-value treatment by addressing fragmentation of
care and management of multimorbidity. “Health in all policies” (73) that address upstream features such as
income and education should be considered to reduce low-value prostate cancer care associated with
significant adverse health related quality of life and cost burdens. Despite a decade’s worth of evidence-based
recommendations of observation for adults with low-risk prostate cancer and a life expectancy of more than 10
years, we observed life expectancy to be a low-ranked predictor of treatment. Physician- and patient- focused
education may be needed to utilize more precise life expectancy estimates in shared decision making of
treatment modalities of low-risk prostate cancer.
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Table 2.1 Patient Characteristics by Treatment Use among Fee-for-Service Medicare
Beneficiaries with Incident Low-risk Prostate Cancer (Linked SEER Cancer Registry and
Medicare claims files, 2009-2014 (n= 13,870)
CM
Treatment
Χ2
p-value
n=4596

33.1

9274

66.9

Multimorbidity
0-2 MM
>2 MM

2157
2439

37.0
30.4

3678
5596

3555
714
327

33.5
31.1
33.9

7057
1580
637

3287
1309

30.8
40.9

7384
1890

3796
497
48
231
24

32.8
35.4
22.6
36.7
36.4

7762
908
164
398
42

Unmarried
Married
Sep/div/wid
Unknown

318
2843
545
890

35.5
29.7
37.6
45.8

577
6742
903
1052

64.5
70.3
62.4
54.2

$2,512-43,709
$43,711-57,34
$57,350-76,87
$76,888250,0

997
1058
1142

30.4
32.6
34.6

2286
2185
2156

69.6
67.4
65.4

1283

34.4

2442

65.6

Income quartile

Education
quartile
1192
1066
1088
1135

33.5
31.6
32.4
34.8

2370
2306
2269
2130

3925
587
**
**

33.4
32.0
**
**

7824
1248
**
**

<0.001

18.128

<0.001

209.023

<0.001

17.902

<0.001

8.371

0.039

3.470

0.325

66.5
68.4
67.6
65.2

Rural group
Metro
Urban
Rural
Unknown

113.674

67.2
64.6
77.4
63.3
63.6

Marital status

0.00-24.0
24-29.0
29.0-34.1
34.1-100

0.078

69.2
59.1

Race
White
Black
Hispanic
Others
Unknown

5.091
66.5
68.9
66.1

Age group
66-74
75 and above

<0.001

63.0
69.6

Life expectancy
10+ years
5-10 years
<5 LE

66.697

66.6
68.0
**
**

Based on 13870 older (age ≥ 66 years) Fee-for-Service Medicare beneficiaries, with continuous enrollment in Medicare Part A & Part B, diagnosed with incident low-risk
prostate cancer (Gleason 6, PSA <10, Stage ≤T2a) between 2009 and 2014.
Age group included 66-74 and 75 and over categories. SEER= Surveillance, Epidemiology, and End Results cancer Registry.
**= Cells suppressed in accordance with Data Usage Agreement due to <11 cell count.Bold values denote statistical significance at the P‐value < .05 level.

19

Continued Table 2.1 Patient Characteristics by Treatment Use among Fee-for-Service
Medicare Beneficiaries with Incident Low-risk Prostate Cancer using Linked SEER Cancer
Registry, 2009-2014 (n=13,870)
Metro group
5.253
0.072
Metro county
3940
33.5
7827
66.5
Non-metro county 648
31.1
1436
68.9
SEER Region
106.457
<0.001
Northeast
838
27.8
2171
72.2
South
1171
30.5
2666
69.5
North Central
433
32.6
896
67.4
West
2154
37.8
3541
62.2
Radiation
oncology quartile
14.578
0.002
0-0.44
1128
31.2
2485
68.8
0.44-0.99
1207
32.3
2527
67.7
0.99-1.47
1085
35.2
1997
64.8
1.48-22.0
1168
34.1
2254
65.9
Urologist quartile
17.438
<0.001
0-1.25
1117
30.4
2562
69.6
1.25-2.38
1255
34.2
2411
65.8
2.38-3.22
1039
34.3
1990
65.7
3.23-28.4
1177
33.9
2300
66.1
Preventative A1c
screening
2.238
0.135
Yes
650
34.6
1226
65.4
No
3946
32.9
8048
67.1
Preventative Flu
vaccination
57.509
<0.001
Yes
2113
30.1
4898
69.9
No
2483
36.2
4376
63.8
Preventative lipid
screening
0.002
0.967
Yes
1283
33.1
2592
66.9
No
3313
33.1
6682
66.9
Primary care
physician visit
44.881
<0.001
Yes
3618
30.6
8205
69.4
No
628
38.9
988
61.1
Based on 13870 older (age ≥ 66 years) Fee-for-Service Medicare beneficiaries, with continuous enrollment in Medicare Part A & Part B,
diagnosed with incident low-risk prostate cancer (Gleason 6, PSA <10, Stage ≤T2a) between 2009 and 2014.
Age group included 66-74 and 75 and over categories.
SEER= Surveillance, Epidemiology, and End Results cancer Registry.
Bold values denote statistical significance at the P‐value < .05 level.
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Figure 2.1 Feature Importance of Treatment Prediction using SHAP values among Fee-for-Service Medicare
Beneficiaries with Incident Low-risk Prostate Cancer using SEER Cancer Registry, 2009-2014 (n=13870)

Top 15 mean SHAP values in descending order of log-odds. Based on 13870 older (age ≥ 66 years) Fee-forService Medicare beneficiaries, with continuous enrollment in Medicare Part A & Part B, diagnosed with
incident low-risk prostate cancer (Gleason 6, PSA <10, Stage ≤T2a) between 2009 and 2014.
Age group included 66-74 and 75 and over categories.
Care fragmentation = Bice-Boxerman continuity of care index to calculate care fragmentation during the 12
month baseline period (See Methods).
SEER= Surveillance, Epidemiology, and End Results cancer Registry.
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Figure 2.2 Positive and Negative Feature Relationships of Treatment Prediction among Fee-for-Service
Medicare Beneficiaries with Incident Low-risk Prostate Cancer using SEER Cancer Registry, 2009-2014
(n=13870)

Mean SHAP values in descending order of log-odds. Based on 13870 older (age ≥ 66 years) Fee-for-Service
Medicare beneficiaries, with continuous enrollment in Medicare Part A & Part B, diagnosed with incident lowrisk prostate cancer (Gleason 6, PSA <10, Stage ≤T2a) between 2009 and 2014.
Age group 66-74 vs. adults over age 74
Multimorbidity group = 3 or more chronic conditions.
Care fragmentation = Bice-Boxerman continuity of care index to calculate care fragmentation during the 12
month baseline period (See Methods).
SEER= Surveillance, Epidemiology, and End Results cancer Registry.
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Figure 2.3 SHAP Partial Dependence Plot of Top 4 Predictive Features of Treatment among Fee-for-Service
Medicare Beneficiaries with Incident Low-risk Prostate Cancer using SEER Cancer Registry, 2009-2014
(n=13870)
A.

B.

C.

D.

SHAP Partial Dependence plots (PDP) of log-odds SHAP values by (A.) Marital status “Married”, (B.) Age
group 66-74, (C) Care fragmentation, and (D) Median Income. Based on 13870 older (age ≥ 66 years) Fee-forService Medicare beneficiaries, with continuous enrollment in Medicare Part A & Part B, diagnosed with
incident low-risk prostate cancer (Gleason 6, PSA <10, Stage ≤T2a) between 2009 and 2014.
Age group 66-74 vs. adults over age 74
Care fragmentation = Bice-Boxerman continuity of care index to calculate care fragmentation during the 12
month baseline period (See Methods).
Median income = County-level median income from Area Health Resource File linkage.
SHAP = Shapley Additive ePlanations.
SEER= Surveillance, Epidemiology, and End Results cancer Registry.
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Figure 2.4 SHAP Partial Density Plot of Life Expectancy and Multimorbidity Predictive Features on
Treatment among Fee-for-Service Medicare Beneficiaries with Incident Low-risk Prostate Cancer using SEER
Cancer Registry, 2009-2014 (n=13870)
A.

B.

SHAP Partial Dependence plots (PDP) of log-odds SHAP values by (A.) PCCI “Life expectancy over 10 years”,
(B.) “Multimorbidity”. Based on 13870 older (age ≥ 66 years) Fee-for-Service Medicare beneficiaries, with
continuous enrollment in Medicare Part A & Part B, diagnosed with incident low-risk prostate cancer (Gleason
6, PSA <10, Stage ≤T2a) between 2009 and 2014.
PCCI = Prostate Cancer Comorbidity Index.
Multimorbidity defined as 1 = two or fewer non-cancer chronic conditions, 2 = three or more non-cancer
chronic conditions.
SHAP = Shapley Additive ePlanations.
SEER= Surveillance, Epidemiology, and End Results cancer Registry.
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CHAPTER 3
3 Associations of Multimorbidity and Patient-reported Experiences of Care with Conservative
Management among Elderly Patients with Localized Prostate Cancer
3.1 Abstract
Background: Many elderly localized prostate cancer patients could benefit from conservative management
(CM). This retrospective cohort study examined associations of patient-reported access to care and
multimorbidity on CM use patterns among Medicare Fee-for-Service (FFS) beneficiaries with localized prostate
cancer.
Methods: We used linked Surveillance, Epidemiology and End Results cancer Registry, Medicare Claims, and
the Medicare Consumer Assessment of Healthcare Providers and Systems survey files. We identified FFS
Medicare Beneficiaries (Age ≥ 66; continuous enrollment in Parts A & B) with incident localized prostate
cancer from 2003–2013 and a completed MCAHPS surveys within 12-months of diagnosis (n=496). We used
multivariable models to examine MCAHPS measures (getting needed care, timeliness of care, and doctor
communication) and multimorbidity on CM use.
Results: Localized prostate cancer patients with multimorbidity were less likely to use CM (adjusted odds
ratio (AOR)=0.42 (0.27- 0.66), P<0.001); those with higher scores on timeliness of care (AOR=1.21 (1.09,
1.35), P< 0.001), higher education attainment (3.21=AOR (1.50,6.89), P=0.003), and impaired mental health
status (4.32=AOR (1.86, 10.1) P<0.001) were more likely to use CM.
Conclusion(s): Timeliness of care was significantly and positively associated, and multimorbidity,
significantly and inversely associated with CM use. Addressing specific modifiable barriers to timely care along
the cancer continuum for elderly localized prostate cancer patients with limited life expectancy, and the
reasons for lower CM use among those with multimorbidity, could reduce the adverse effects of overtreatment
on health outcomes and costs.
Text pages: 17, Tables: 4, and 2 Figures
Keywords: prostate cancer, conservative management, active surveillance, multimorbidity, patient-centered
care.
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3.2 Introduction
Conservative management (CM) has emerged as a common disease management approach for older
adults with localized prostate cancer.(63) CM use is supported by high-level evidence for localized prostate
cancer patients with low or favorable intermediate risk disease or higher risk disease with limited life
expectancy.(6) CM includes protocols for low or intermediate risk prostate cancer, such as follow-up biopsies
and PSA testing, or “watchful waiting” for patients with less than 5 years of life expectancy. Use of CM among
patients with low‐risk prostate cancer or limited life expectancy improves health‐related quality of life (ie,
urinary, bowel, and/or erectile dysfunction) and could reduce excessive annual health‐care costs of
overtreatment by $1.2 billion.(10,64)
CM decisions are complex as 60% of older adults (age > 65 years) with localized prostate cancer have
pre-existing multimorbidity.(47,48) Multimorbidity affects life expectancy(47) and more than 50% of patients
with multimorbidity seek care from three or more healthcare specialists.(50) Patients with multimorbidity and
cancer may be vulnerable to poor quality of cancer care and have prompted greater attention in measuring,
monitoring, and incentivizing patient‐centered care.(15) Measures of patient‐centered care, such as patient‐
reported experiences with care include domains of physician communication, timely care, and perceptions of
getting needed care, are increasingly used as quality measures by health plans, medical groups, and physician
practices. Positive patient‐reported experience scores are associated with adherence to medical advice,
improved clinical outcomes, and lower utilization of unnecessary health‐care services(29,74) such as
overtreatment of low‐risk localized prostate cancer.
Patient‐reported experiences may differ by multimorbidity status, which may further complicate or
facilitate treatment choices for low‐risk prostate cancer.(75) Identifying specific measures of patient‐reported
experiences that facilitate CM use among patients with incident localized prostate cancer and multimorbidity is
needed to promote evidence‐based cancer care.(30) For example, in colorectal cancer populations, patient‐
reported experiences with perceived timely care are associated with evidenced‐based follow‐
up.(31) Understanding the relationship between patient‐reported experiences of care on CM use can inform
patient‐centered care approaches to improve adoption of CM use, thereby reducing the adverse effects of
overtreatment among older patients with multimorbidity and localized prostate cancer.
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Despite the importance of patient‐reported experiences, CM studies primarily focus on disease
characteristics, clinical, and sociodemographic factors.(27,38,39,63) To date, no studies have investigated the
impact of patient‐reported experiences on CM use among medically complex patients with localized prostate
cancer. Therefore, the primary objective of this study is to examine the associations of multimorbidity and
patient‐reported experiences on CM use among Fee‐for‐Service (FFS) Medicare beneficiaries with localized
prostate cancer using Consumer Assessment of Healthcare Providers and Systems (MCAHPS®) patient
surveys and Medicare claims linkages.
3.3 Methods
The study cohort included men diagnosed with localized prostate cancer defined as American Joint
Committee on Cancer stage T2a or less,(6) aged 66 or older, with continuous enrollment in FFS Medicare Parts
A and B throughout the study period (Figure 3.1).
Date of incident localized prostate cancer diagnosis was used as an index date and 12 months before
diagnosis was used as the baseline period. During the baseline period, we identified multimorbidity using
Medicare claims and calculated life expectancy estimates.
We also defined the “CM measurement” period as 12 months after diagnosis. During this period, we
identified CM based on validated methods for claims data.(53)
As MCAHPS surveys can be administered at varying points during the post diagnosis period, we
followed individuals for an additional period of 12 months. Thus, our follow‐up period consisted of 24 months
after incident localized prostate cancer diagnosis.
To account for varying months from diagnosis to survey administration, we included time from
diagnosis to survey as one of the independent variables in the models. However, as this variable was not
significant and did not affect our main results, we did not include time from diagnosis to survey administration
variable in the final model. As a sensitivity analysis, we also estimated CM use during 24 months after
diagnosis (Appendix 7.3).
Data sources
The Surveillance, Epidemiology and End Results (SEER) cancer registry contains tumor and
demographic information for patients diagnosed with cancer while residing in a SEER region. We derived
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Medicare eligibility from the SEER data (Figure 3.1). We extracted fee-for-service Medicare claims from
Medicare Provider Analysis and Review (MEDPAR), Carrier Claims, Outpatient Claims, Home Health Agency,
and Durable Medical Equipment files.
Medicare Consumer Assessment of Healthcare Providers & Systems (MCAHPS®) surveys,
administered by the CMS, use standardized and validated questionnaires to collect information on patient‐
reported experiences with health‐care providers.(40) MCAHPS collection methodologies use a weighted
probability sampling procedure covering all the 50 US states, DC, and Puerto Rico, which are then linked to
SEER patients.(40,41)
Area Health Resource File (AHRF) files were linked via MEDPAR FIPS state and county codes and were
used to calculate radiation oncologist and urologist densities.(42) Census files were linked to calculate county‐
level median income quartiles.
Dependent Variable
We operationalized CM use as the absence of curative treatment within 12 months after incident
localized prostate cancer. Treatment was identified using International Classification of Diagnosis 9th edition
(ICD9), ICD9 procedure codes, and Healthcare Common Procedure Coding System (HCPCS) codes from FFS
Medicare claims (Appendix 7.4).(6,38,53)
Key Independent Variables
The multimorbidity framework developed by the United States Department of Health and Human
Services for guiding programs, practice, and policy guided the selection of chronic conditions as follows:
arthritis, asthma, coronary artery disease, congestive heart failure, chronic kidney disease, chronic obstructive
pulmonary disease, cardiac arrhythmias, acute myocardial infarction, dementia, diabetes, depression,
hepatitis, hyperlipidemia, hypertension, human immunodeficiency virus, osteoporosis, substance abuse,
schizophrenia, stroke, anemia, and lower limb fracture.(55) The most common definition of multimorbidity is
the concurrent presence of two or more conditions in the same individual.(76) We defined multimorbidity as
the presence of three or more conditions in the same individuals as older men diagnosed with prostate cancer
at age 65 or higher are at high risk for competing risk mortality. For example, among men with three or more
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comorbid conditions, aged 61‐74 and 75 years or older, 10‐year other cause mortality is 40% and 71%,
respectively.(77)
Prostate cancer comorbidity index (PCCI), a weighted comorbidity index validated prostate cancer
patient populations, was used to predict 5‐ and 10‐year life expectancy in prostate cancer patient
populations.(77) PCCI was calculated during the baseline period to estimate 5‐ and 10‐year life expectancy.
PCCI was categorized into three groups: 0–8 (>10‐year life expectancy); 9 to 13 (5‐ to 10‐year life expectance);
and > 13 (<5‐year life expectancy). In all models, PCCI total 0‐8 was used as the reference group.
Published research in prostate cancer patients often uses Charlson Comorbidity Index (CCI); therefore,
we conducted a supplemental analysis using CCI. In these analyses, CCI scores were dichotomized with “0‐1” as
the reference group.(78)
We included three MCAHPS composite measures— “getting needed care,” “getting care quickly,” and
“doctor communication”—which rates the ability to get needed appointments, timeliness of care when care is
needed, and how well the physician communicated. Patients report experiences with health‐care access in the
last 6 months. MCAHPS surveys have been extensively validated for measuring patient‐reported access to care
and are commonly used for quality improvement as well as value‐based purchasing initiatives.(40) MCAHPS
are based on a 0‐100 scale with 0 representing the lowest and 100 representing the highest score; we examined
the effect of 10 unit changes in composite items on the dependent variable.
Management of preexisting multimorbidity and shared prostate cancer treatment decision‐making
requires the use of limited resources (ie, time to manage chronic conditions and availability of health‐care
professionals and resources). Therefore, for other independent variables, the competing demands model was
used to conceptualize factors known to affect localized prostate cancer treatment selection within clinician,
patient, and practice ecosystem domains.(38,53,79) (Figure 3.2).
Multivariable models were adjusted with independent variables: diagnosis year group (2003‐2009 and
2010‐2013), low‐risk prostate cancer (operationalized as Gleason Score ≤ 6 and PSA test ≤ 10 ng/mL or
Gleason Score>=7 or PSA> = 10 ng/mL), self‐reported general and mental health status, education‐level, zip‐
code income quartiles, and county‐level quartiles of urologists and radiation oncologists per 10,000 persons
over age 65.
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Our analyses include several case‐mix adjustment variables such as age, education, general health
status, mental health status, income level, and race. Secondary analyses using additional recommended case‐
mix adjustment variables, such as dual‐eligible Medicaid respondents, “proxy” survey completion, and time
from cancer diagnosis to survey completion, did not significantly improve model specification.(80)
To assess the potential influence of missing data, we examined missing data patterns using covariate‐
dependent missingness methods.(81) Mean values were imputed to independent variables of interest. For
categorical variables, including general and mental health status, missing data indicators were created and
included as a separate category in the regression models.
Chi‐square tests and t tests were used to identify significant group differences in CM use by categorical
variables. Multivariable models were fit using separate unadjusted and adjusted logistic regressions to identify
independent and interactive associations of multimorbidity and patient care experiences on CM use.
All statistical tests were two‐sided with a 5% Type I error rate and were completed in STATA (StataCorp,
College Station, TX).
3.4 Results
The study cohort was predominantly non‐Hispanic, whites (84.5%). The median age at diagnosis was
72.8 years and did not differ by year of diagnosis (2003‐2009:73.6 = M, 5.38; 2010‐2013:73.6 = M, SD = 5.14).
Average composite scores for doctor communication, getting needed care, and getting care quickly were 91.0
(SD = 12.2), 88.6 (SD = 15.6), and 70.8 (SD = 21.7), respectively.
Overall, 33.5% used CM, defined as no curative treatment within 12 months of incident localized
prostate cancer diagnosis. Use of CM was only marginally higher in men with low‐risk relative to those with
higher‐risk disease (≤ cT2a and PSA>= 10 ng/mL or Gleason Score > 6) (38.7% vs 30.9%, respectively, P = .08)
(Table 3.1). High‐school graduation, college education, low‐risk prostate cancer diagnosis, and mental health
status were significantly more frequent among patients using CM (Table 3.1). CM use by localized prostate
cancer patients with higher‐risk disease was 30.9%. Higher‐risk disease was significantly more common among
age groups 75+ (75.9%) vs 66‐74 (62.4%) (P = .002) and significant differences by patients with multimorbidity
24.6% (n = 45) vs those without multimorbidity 38.7% (n = 58), (Χ2 = 7.65, P = .006) were observed.
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In our study cohort, 57.2% had multimorbidity. Patients 75 years or older were significantly more likely
to have multimorbidity than those aged 66‐74 years (64.4% vs 53.4%). Blacks had a higher percentage of
multimorbidity as compared to whites (76.1% vs 53.9%). Patients with multimorbidity using treatment (n =
207) did not differ significantly by patient, clinician, or practice ecosystem factors except for mental health
status of excellent/very good (74.6%) and good (77.5%) vs patients using CM (P = .031). Patients with
multimorbidity and higher‐risk disease (n = 183) significantly more frequently used treatment if aged 66‐74
(82.5%) (P = .011). Average composite scores for doctor communication, getting needed care, and getting care
quickly did not differ by multimorbidity status. CM use was significantly lower in men with vs without
multimorbidity (27.1% vs 72.9%, respectively, P < .001).
Average getting care quickly composite scores (ie, timely care) were higher for those with CM use as
compared to those without CM use (Table 3.2). CM use significantly differed by PCCI categories, with lower
percentages among groups with less than 10 (27.0%) and 5 (27.0%) vs more than 10 (38.9%) years of life
expectancy (Χ2 = 7.82, P = .020) (Table 3.2).
PCCI life expectancy groups did not statistically differ by CM use. Higher‐risk patients reporting fair or
poor mental health status (62.1%; P = .002) vs excellent mental health status, and college education (33%) or
high‐school graduates (37.5%) vs no high‐school graduation (13.7%), significantly used CM more frequently.
Getting care quickly composite scores were significantly higher among higher‐risk patients (n = 333) using CM
(M = 75.8) vs curative treatment (M = 69.8), (t=−2.43, CI 95%= 69.3, 73.9, P = .016).
Multimorbidity was significantly and inversely related to CM use in unadjusted logistic regression
analyses (odds ratios (OR) = 0.55; 95% CI = 0.35, 0.75). Adjustment for other factors, including timeliness of
care, further strengthened this association (adjusted OR (AOR) = 0.42, CI 0.27‐ 0.66) (Table 3.3); additional
models adjusting for other patient experience domains or CCI were not significant. Getting care quickly showed
a significant, positive association with CM use in both the unadjusted analyses (OR = 1.15; 95% CI = 1.05, 1.27)
and the fully adjusted models (AOR = 1.21; 95% CI = 1.09, 1.34). In models including PCCI life expectancy
categories, less than 10‐ and 5‐year life expectancy were inversely associated with CM use (Appendix 7.2).
CM use was also significantly and positively associated with fair/poor mental health status, low‐risk
prostate cancer diagnosis, college education or more, and high‐school graduation in all adjusted models (Table
31

3.3; Appendix 7.1 and 7.2). We found no evidence for a modifying effect of patient‐experience variables,
multimorbidity, PCCI, or other independent variables on the observed associations.
3.5 Discussion
In this study, we assessed the independent associations of multimorbidity and patient‐reported
experiences with care on CM use among older men with localized prostate cancer. Despite proven benefits of
CM, one in three (33.5%) of all men with localized prostate cancer, and only two in five (41%) men over the age
of 75 years, used CM. Our estimates of CM use among patients with localized prostate cancer are lower than
those reported in recent investigations using SEER‐Medicare data (42.1% in 2015)(63) but higher than
reported in an investigation of Michigan Medicare beneficiaries (22.3% in 2014).(53) We speculate that these
differences could be due to variation in study population characteristics (ours included prostate cancer patients
from many regions of the US) and geographic practice patterns.(82–84)
Multimorbidity and life expectancy are critical components of patient counseling after a localized
prostate cancer diagnosis as many older men do not live long enough to benefit from treatment. Patients with
low or favorable intermediate‐risk disease or higher‐risk disease with limited life expectancy could avoid
significant urinary, erectile, and rectal treatment morbidities without increasing the risk of prostate cancer‐
specific mortality with CM.(85,86) However, in our study, men with multimorbidity were significantly less
likely to use CM compared to those without multimorbidity after controlling for age, low‐risk prostate cancer,
and other sociodemographic variables. We speculate that men with multimorbidity and low‐risk cancer may
not opt for treatment because they may have a preference for immediate cure (ie, “take care of it”)(87) and may
not want to add one more condition that requires long‐term management. Furthermore, men with
multimorbidity may fear nontreatment regret,(88) emotional distress,(89) and anxiety.(90) Strong
multidisciplinary management strategies, including significant psychological support from primary care
physicians and specialists (ie, urologist and/or medical and radiation oncologists), are needed to mitigate
decisional conflict(91) and therefore facilitate CM use.(27)
In adjusted models, including validated life expectancy measures for prostate cancer survivors, patients
meeting evidence‐based criteria2 for CM were 58% less likely to use CM based on life expectancy alone (ie, less
than 5 years). Previous studies using CCI report both positive and negative relationships between comorbidity
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burden and CM use in Medicare FFS populations.(67,68,92) In a supplemental analysis in this study, CCI was
not significantly associated with CM use. Taken together, these findings suggest that clinical and population
differences in comorbidity definitions are likely to account for mixed findings in several previous
investigations.(69) By defining multimorbidity using a list of conditions prioritized by policy makers in the
US,(55) our study made a unique contribution to this field. However, as pointed out by a systematic review that
current life expectancy prediction tools lack both practical and theoretical utility,(34) comorbidity measures
that can be easily operationalized in a clinical setting are needed. Recently, age‐adjusted indexes, such as the
PCCI used in our study, were developed to provide life expectancy estimates in patients with prostate
cancer.(54) Certain types (cardiovascular disease) and combinations (cardiometabolic and respiratory)(65) of
chronic conditions are associated with treatment regardless of patient, clinician, and health‐care ecosystem
factors. Additional research is needed to understand the relationship between more precise estimates of life
expectancy and multimorbidity on CM use in FFS Medicare populations.
In our study, patient‐reported experiences, specifically timeliness of care, were positively associated
with CM use. Patients with higher timeliness of care scores were significantly more likely to use CM after
adjusting for demographic, clinical, socioeconomic, and health‐care system factors. Timely access to care for
localized prostate cancer patients is not limited to initial diagnosis of prostate cancer, but the opportunity and
ease by which a patient is able to utilize needed services along the continuum of care throughout
survivorship.(93) Choices for elderly localized prostate cancer patients involve selecting curative and noncurative treatments with trade‐offs in efficacy, potential adverse quality of life effects, and competing risk
mortality. MCAHPS timeliness of care domains, such as perceived barriers to appointment scheduling, are
fundamental to shared decision‐making among multiple health‐care providers that significantly influence
localized prostate cancer treatment choice.(94–96) We speculate that patients with higher timely care ratings
may choose CM because they may have a favorable perception of health‐care system capacity to provide
services once a need is detected.
Our study findings have important policy implications. Currently, no value‐based mechanisms exist to
support the use of CM in Medicare FFS populations. Existing literature also suggest that CM use in FFS system
varies among physician practices by 5.1%‐71.2%.(84) Emerging oncology care models by CMS may need to
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incorporate risk‐adjusted CM use as a quality indicator along the cancer care continuum(97) to promote CM
use among men with localized prostate cancer. Recently, the NCCN Quality and Outcomes committee
identified significant gaps in evaluating high‐quality cancer care with patient experience measures and
evidence‐based practice.(85) More research is needed to identify specific barriers to timely care and how
validated patient‐reported experience measures can be used to support evidence‐based management of
localized prostate cancer patients in oncology care models.

We also observed that elements of social determinants, such as education, were associated with CM use.
Although educational attainment may not be modifiable among older adults, initiatives such as “health in all
policies” by World Health Organization and the Centers for Disease and Prevention Control “integrate and
articulated health considerations” into community health policy.(73) These experts concluded that social,
economic, and physical environments have a significant impact on the health of an individual and these effects
should be considered in the development of all public policies and programs.
3.6 Strengths and Limitations
The SEER‐CAHPS data linkage is a robust and unique resource that provides an ideal opportunity to
study patient‐centered care delivery of contemporary treatment patterns among patients with localized
prostate cancer and multimorbidity. We build on previous findings by including validated estimations of life
expectancy and definitions of multimorbidity to access the impact of comorbid conditions on patterns of
contemporary treatment options for older localized prostate cancer patients.
Our study results must be interpreted with important limitations. MCAHPS surveys request patient‐
reported experiences with care “in the last 6 months”.(40) Due to relatively small sample size, we included
surveys completed within 6 months after localized prostate cancer diagnosis which may overlap with the
baseline period. However, our results were robust to multivariable adjustments for time between cancer
diagnosis and survey completion. Due to MCAHPS survey administration processes and collection, we cannot
directly attribute MCAHPS composite ratings to physician specialty or the prostate cancer diagnosis; instead,
our results are generalizable to the entire patient experience after diagnosis which may include multiple care
providers for multiple conditions. The study sample comprised of predominantly non‐Hispanic white, urban
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adults, potentially limiting generalizability to ethnic minorities, rural, or other populations. Our study was
restricted to Medicare FFS enrollees 65 years or older and may not be generalizable to younger adults or
individuals on private insurance. Lastly, due to sample size limitations, we were unable to analyze the
relationship of individual chronic conditions with CM use.
3.7 Conclusions
Our results highlight the effect of patient‐reported experiences, multimorbidity, and life expectancy on
CM use among older men with localized prostate cancer. While factors such as multimorbidity and life
expectancy are critical clinical components that may affect the choice of CM vs over treatment, our study
highlights the role of nonclinical factors, specifically patient‐reported experiences with care on treatment of
localized prostate cancer. Our findings support a “population health‐based” oncology care model in which both
clinical and nonclinical factors, such as patient‐reported experiences, are integrated to promote CM use and
avoid overtreatment among older men with localized prostate cancer.
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Table 3.1 Patient Characteristics by Conservative Management among Fee-for-Service Medicare Beneficiaries
with Incident Localized Prostate Cancer using Linked SEER Cancer Registry with MCAHPS, 2002-2013
(n=496)
CM
No CM
N
ALL

%

166

N

33.5

%

330

75+

102

31.7

220

68.3

64

36.8

110

63.2

Race
White

140

33.4

279

66.6

Black

15

32.6

31

67.4

Other

11

35.5

20

64.5

Marital Status
Married

115

32.9

235

67.1

Unmarried

22

34.9

41

65.1

Unknown

29

34.9

54

65.1

Income quartiles
First

38

33.3

76

66.7

Second

39

33.6

77

66.4

Third

38

31.1

84

68.9

Four

51

35.4

93

64.6

Education
College or more

100

36.6

173

63.4

High School Grad.

42

35.9

75

64.1

No High School Grad.

13

18.8

56

81.2

General health status
Excellent/Very Good

59

35.5

107

64.5

Good

54

28.6

135

71.4

Fair/Poor

47

37.6

78

62.4

Mental health status
Excellent/Very Good
Good

p-value

66.5

Age in Years
66-74

Χ2

104

31.6

225

68.4

34

30.1

79

69.9

1.32

0.250

0.07

0.964

0.2

0.905

0.54

0.909

8.11

0.017

3.32

0.19

11.3

0.004

Fair/Poor
22
16
57.9
42.1
Bold values denote statistical significance at the P‐value < .05 level.
Based on 496 older (age ≥ 66 years) Fee‐for‐Service Medicare beneficiaries, with continuous enrollment in
Medicare Part A & Part B, diagnosed with incident localized prostate cancer between 2003 and 2013.
Abbreviations: CM, Conservative management; MCAHPS, Medicare Claims and the Medicare Consumer
Assessment of Healthcare Providers and System surveys; SEER, Surveillance, Epidemiology, and End Results
cancer Registry.
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Table 3.1 “continued”
Urologist density
0 to 1.41

41

33.1

83

66.9

1.41 to 2.49

33

26.6

91

73.4

2.5 to 3.46

51

39.8

77

60.2

3.47 to 10.2

41

34.2

79

65.8

Radiation oncologist density
0 to 0.44

37

29.8

87

70.2

0.45 to 1.07

41

33.1

83

66.9

1.07 to 1.49

52

41.6

73

58.4

1.51 to 5.35
SEER region
Northeast

36

29.3

87

70.7

33

35.5

60

64.5

South

35

30.4

80

69.6

North-central

13

22.4

45

77.6

West

85

37

145

63.0

Metro Status
Metro
Non-Metro

138

34.3

264

65.7

28

29.8

66

70.2

Diagnosis Year
2002-2007

96

32.3

201

67.7

2008-2013

70

35.2

129

64.8

Low-risk prostate cancer
Yes

63

38.7

100

4.99

0.173

5.43

0.143

5.09

0.166

0.71

0.401

0.44

0.509

2.93

0.087

61.3

No
103 30.9 230
69.1
Bold values denote statistical significance at the P‐value < .05 level.
Based on 496 older (age ≥ 66 years) Fee‐for‐Service Medicare beneficiaries, with continuous enrollment in
Medicare Part A & Part B, diagnosed with incident localized prostate cancer between 2003 and 2013.
Abbreviations: CM, Conservative management; MCAHPS, Medicare Claims and the Medicare Consumer
Assessment of Healthcare Providers and System surveys; SEER, Surveillance, Epidemiology, and End Results
cancer Registry.
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Table 3.2 Multimorbidity and Patient Experiences by Conservative Management among Fee-for-Service
Medicare Beneficiaries with Incident Localized Prostate Cancer using Linked SEER Cancer Registry with
MCAHPS, 2002-2013
CM
No CM
N
%
N
%
Χ2
p-value
166
33.5
330
66.5
Multimorbidity

12.1

<0.001

7.82

0.020

Yes

77

27.1

207

72.9

No

89

42.0

123

58.0

< 5 years life expectancy

20

27.0

54

73.0

≥ 5 and < 10 years life expectancy

41

27.0

111

73.0

≥10 years life expectancy

105

38.9

165

61.1

Getting Needed Care

Mean
87.1

SE
1.33

Mean
89.3

SE
0.81

t-Value
1.48

p-value
N.S.

Getting Care Quickly

75.0

1.48

68.7

1.25

-3.06

0.002

Doctor/Patient Communication

89.8

1.05

91.6

0.63

1.61

N.S.

PCCI
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Table 3.3 Unadjusted (UOR), Adjusted Odds Ratios (AOR) and 95% Confidence Intervals (CI) of
Multimorbidity, Mental Health, Timeliness of Care, Low-risk Prostate Cancer, and Education on Likelihood of
Conservative Management Use among Fee-for-Service Medicare Beneficiaries with Incident Localized
Prostate Cancer using Linked SEER Cancer Registry with MCAHPS, 2002-2013 (N = 496).
UOR [95% CI]
Patient Experience: Getting Care Quickly

AOR [95% CI]

p-value

Multimorbidity

p-value

0.51

[0.35 - 0.75] 0.001

0.42 [0.27 - 0.66] <0.001

1.15

[1.05 - 1.27]

0.003

1.21

[1.09 - 1.35] <0.001

1.41

[0.95 - 2.08] 0.088

1.76

[1.14 - 2.72]

2.97

[1.50 - 5.90] 0.002

4.32

[1.86 - 10.1] <0.001

College or more

2.49

[1.30 - 4.78] 0.006

3.21 [1.50 – 6.89] 0.003

High-school graduate

2.41

[1.18 - 4.92]

3.53

Yes
No (Ref.)
Getting Care Quickly
Low-risk prostate cancer
Yes

0.01

No (Ref.)
Mental Health Status
Fair/Poor
Ex/VG/Good (Ref.)
Education
0.015

[1.59-7.83]

0.002

No high-school graduation (Ref.)
Patient Experience: Getting Need Care
Multimorbidity
0.088

Yes

0.45 [0.30 - 0.70] <0.001

No (Ref.)
Getting Needed Care

N.S.
Patient Experience: Doctor Communication

-

-

N.S.

Multimorbidity
0.088

Yes

0.45 [0.29 -0.68] <0.001

No (Ref.)
Doctor Communication

-

-

39

N.S.

-

-

N.S.

Figure 3.1 Cohort Selection and Exclusion
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Figure 3.2 Adapted Competing Demands Framework
Clinician domain

Life expectancy, Multimorbidity,
cancer risk group

Study
Outcomes

Patient domain
Age, race, marital status, education

Practice ecosystem
Diagnosis year, SEER region,
Urologist density, Radiation
oncologist density, metro status
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CHAPTER 4
4 Healthcare Expenditures Associated with Low-value Care among Older Men with Incident
Localized Prostate Cancer: Statistical and Machine Learning Approaches
4.1 Abstract
Background: Older adults with incident localized prostate cancer represent a large, medically complex
population at risk of low-value care in the form of overtreatment. Conservative management (CM), or nontreatment of prostate cancer with little cancer specific mortality risk, can reduce the adverse effects of
overtreatment. Other types of low-value care services are associated with high, compounding “downstream”
costs and may be useful for predicting cancer survivorship costs.
Research Objective: Use statistical and machine learning approaches to estimate the association of lowvalue care use prior to incident prostate cancer diagnosis on average non cancer related total healthcare
expenditures 12-24 months after diagnosis. Generalized linear models (GLM) with log-link and gamma
distribution were used to estimate total healthcare cost. Predictive feature importances of healthcare costs and
non-linear relationships were estimated using the XGBoost Machine Learning (ML) algorithm and SHapley
Additive exPlanations (SHAP).
Study Design: Retrospective cohort study.
Population Studied: We used linked Surveillance, Epidemiology, and End Results cancer Registry, Medicare
Claims, Census, and Area Health Resource files identify Medicare Fee-for-Service beneficiaries with continuous
enrollment in Parts A & B and incident localized prostate cancer from 2005 to 2014 (n=75671). We identified
20 low-value care measures 12 months prior to localized prostate cancer diagnosis using SEER-Medicare
registry and claims files. Conservative management was defined as no treatment 0-12 months after diagnosis.
Non cancer related total healthcare expenditures were defined as all costs independent of cancer treatment
modalities 12-24 months after diagnosis.
Principal Findings: Overall, 25.2% used low-value care services in 12 months prior to cancer diagnosis.
Screening for asymptomatic carotid artery stenosis, Magnetic Resonance Imaging (MRI) for low-back pain,
and traction for low-back pain were the most frequent low-value care procedures. Overall 18.1% used CM and
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use of any low-value care was lower among patients using CM (15.2%), with MRI for low-back pain, traction for
low-back pain, and asymptomatic carotid artery stenosis more frequent among patients using treatment.
In adjusted GLM models, every 1-unit increase in low-value care use was associated with an $858.82 increase
in healthcare expenditures. Multimorbidity (physical condition count), care fragmentation, and conservative
management use were the top 3 predictors of healthcare expenditures with the highest absolute mean SHAP
values.
Conclusions: We found incremental low-value healthcare use before incident prostate cancer diagnosis was
significantly and positively associated with long-term non-cancer related costs. Using ML, both low-value care
and CM use were highly ranked important features of cost prediction 12-24 months after incident prostate
cancer diagnosis.
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4.2 Introduction
Low-value care, defined as unnecessary tests or treatment lacking a net clinical benefit to the patient,
contribute to avoidable morbidities and excessive healthcare costs.(17) Low-value care is prevalent among
elderly patients, affecting 1 in 4 Medicare beneficiaries(18) and accounting for $75.7 - $101.2 billion in annual
healthcare costs.(19,20) Use of low-value healthcare services among medically complex patients can lead to
cascades of unnecessary down-stream care, leading to costs as high as 10 times the original low-value
healthcare service.(21)
Adults with incident localized prostate cancer represent a large, medically complex population at risk of
low-value care in the form of overtreatment. Older adults with localized prostate cancer have high rates of
multimorbidity and often experience care fragmentation that present barriers to shared decision making and
evidence-based recommendations.(25) These adults may be at risk for receiving low-value care, augmenting
down-stream costs. Many studies have examined comparative costs between different prostate cancer
treatment modalities including conservative management (CM) (32); however, long term costs associated with
overtreatment or low-value care remain unknown.
Recently, machine learning algorithms have been used to identify high-cost patients (98), including, for
example, high-cost breast cancer patients (99). However, the potential predictive effects of low-value care on
non-cancer related total healthcare expenditures among medically complex localized prostate cancer survivors
remains little explored.
The primary objective of this paper is to examine whether low-value care is a leading predictor of longterm (12-24 months after diagnosis) non-cancer related expenditures among older adults with incident
localized prostate cancer using machine learning algorithms and model agnostic interpretations. We used
traditional generalized linear models to examine the association of life expectancy, high- and low- value care
use, and care fragmentation on healthcare expenditures 12-24 months after the diagnosis of localized prostate
cancer.
4.3 Methods
Design
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This study used a retrospective longitudinal design with a 12-month baseline and a 24-month follow-up
period. The baseline period comprised the 12-month period before date of localized prostate cancer diagnosis.
The follow-up period included the 24-month after localized prostate cancer diagnosis. Healthcare expenditures
were calculated during the second half of the follow-up period (12-24 months).
Data sources
This study used the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked data files.
SEER-Medicare data includes data on all incident prostate cancer cases occurring in 18 regions throughout the
United States. Incident prostate cancer, prostate cancer specific clinical information (i.e., Gleason Score and
Prostate-specific antigen values), and cancer staging information were derived from the SEER database.
Medicare claims were derived from inpatient, outpatient, and other files linked to SEER.
Area Health Resource File (AHRF) files were linked via MEDPAR FIPS state and county codes and were
used to calculate radiation oncologist and urologist densities. Census files were linked to calculate county-level
median income quartiles.
Study population
Patients (age ≥ 66 years) diagnosed with localized prostate cancer during the study period (2005-2014)
were included in the study population. Cancer diagnosis was identified using International Classification of
Diseases for Oncology (ICD-9). Localized prostate cancer was defined as cancer stage ≤T2a.
Study inclusion/exclusion criteria:
Patients with localized prostate cancer were included in the study if alive and continuously enrolled in
Medicare Parts A and B throughout the baseline and follow-up periods. Patients with missing cancer stage, PSA
values, Gleason Scores were excluded. Patients diagnosed with prostate cancer at autopsy were excluded
(Appendix Figure 7.7).
Dependent variable/target
Total healthcare expenditures were calculated by summing inpatient (MEDPAR), outpatient (Outsaf,
NCH), and “other” (durable medical equipment, and home health agency) claims. To compare non-cancer
related healthcare expenditures, we subtracted treatment-related costs from total healthcare expenditures. All
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expenditures were estimated 12-24 months after localized prostate cancer diagnosis. Consumer price index
(CPI) was used to adjust all expenditures to 2016 constant dollars. (100)
Key Independent variables/features
Low-value care
Various professional societies identify medically unnecessary and/or potentially harmful procedures,
tests, and treatments for Choosing Wisely in an international effort to reduce low-value care.(20,22) Low-value
healthcare services were operationalized using a claims-based algorithm representing Choosing Wisely
campaign recommendations. The Low-value care algorithm included procedure, diagnosis, hospitalization, and
BETOS codes using previously published methods.(60–62)
Other independent variables
Conservative management
Conservative management was estimated within the first 12 months of the 24-month follow-up period
using a validated claims-based algorithm.(53) Patients without treatment claims were designated as using
conservative management.
Multimorbidity
The multimorbidity framework developed by the United States Department of Health and Human
Services for guiding programs, practice, and policy guided the selection of chronic conditions as follows:
arthritis, asthma, coronary artery disease, congestive heart failure, chronic kidney disease, chronic obstructive
pulmonary disease, cardiac arrhythmias, acute myocardial infarction, dementia, diabetes, depression,
hepatitis, hyperlipidemia, hypertension, human immunodeficiency virus, osteoporosis, substance abuse,
schizophrenia, stroke, anemia, lower limb fracture.(55) We used clinically meaningful cut points (77) of
multimorbidity (i.e., >2 chronic conditions) in descriptive analyses and included total counts of mental and
physical health conditions in ML models.
Prostate cancer comorbidity index
Prostate cancer comorbidity index (PCCI) is a weighted comorbidity index validated in prostate cancer
patient populations to predict 5 and 10 year life expectancy.(54) PCCI was calculated during the baseline period
to estimate 5 and 10 year life expectancy. PCCI was categorized into 3 groups: 0-8 (> 10-year life expectancy); 9
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to 13 (5-10-year life expectancy); and > 13 (< 5-year life expectancy). In GLM models, PCCI total representing
>10 years of life expectancy was used as the reference group. In ML models, we included PCCI as a continuous
variable.
Managing pre-existing conditions and an incident prostate cancer diagnosis requires the use of limited
patient, clinician, and practice ecosystem resources; patients must balance the management of several chronic
conditions and participate in shared-decision making to select prostate cancer management within a practice
environment with variation in supply and demand of healthcare resources (i.e., supply of clinician specialists).
Therefore, a competing demands framework and previous literature reviews were used to guide the selection of
other independent variables known to affect low-value care and prostate cancer treatment selection within
patient, clinician, and practice ecosystem domains.(20,27,32,101)
Other independent variables included: diagnosis year group (2003-2009 and 2010-2013), low-risk
prostate cancer (operationalized as Gleason Score ≤ 6 and PSA test ≤ 10 ng/mL), education (Less than highschool graduation and college graduation per 10,000 persons over age 65), income, urologist, and radiation
oncologist quartiles (per 10,000 persons over age 65).
We used a modified version of the Bice-Boxerman continuity of care index to calculate care
fragmentation.(56) The continuity of care index represents the concentration of visits per patient among health
care providers based on visit number, proportion of encounters to each provider, and total number of visits. We
used physician specialty codes representing primary care, oncology, and various specialist visit encounters;
where n is the total number of visits, nk is the total number of visits associated with a physician specialty, and k
the total number of physician specialty codes.(59) For example, multiple encounters with a single provider
would result in a score of zero, however, multiple encounters among several health care providers would result
in a score approaching 1. We included many specialties as patients with multimorbidity and/or limited life
expectancy may require services from multiple specialists. Care fragmentation was measured during the 12
month baseline period.
All independent variables were calculated in the 12 months before cancer diagnosis.
Statistical Analysis
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Chi-square tests and t-tests were used to identify significant group differences in low-value care and CM
use by categorical variables. Generalized linear models (GLM) with log-link and gamma distribution were used
to estimate total healthcare cost. GLM transforms the mean cost directly, reversing the transformation is
possible without bias estimation of mean cost. Differences between cost associated with each independent
variable of interest and the exponentiated intercept term were reported as the incremental average cost (i.e.,
mean) associated with independent variables of interest. GLMs were fit using separate unadjusted and adjusted
regressions to identify independent and interactive associations of key independent variables and total
healthcare expenditures. All statistical tests were 2-sided with a 5% Type I error rate and were completed in
SAS (SAS Institute Inc., Cary, NC, USA. Version 9.4, using Windows 10).
Machine learning
We used the XGBoost regression, a decision-tree ensemble machine learning algorithm, to determine
the association of low-value care to healthcare expenditures.
Model training was conducted on 70% of the original data with 10-fold cross validation based on the
original data set. Hyperparameter adjustments were made during training interactions to address overfitting.
Healthcare expenditures were log transformed to approximate a normal distribution. Prediction performance
was assessed on unseen data by reserving a 30% stratified random sample of the original data (i.e., the test set).
Model tuning and test prediction performance were assessed using Residual Mean Squared Error and R2.
Hyperparameter tuning parameters codes are available in Supplemental Materials 1.
SHAP is an additive feature attribution method that provides consistent, locally accurate,
individualized feature attributions based on conditional expectation. SHAP is an improvement over other
feature importance methods that utilize model performance metrics (i.e., gain/accuracy) subject to
inconsistency bias. SHAP values can be sorted to illustrate feature importance and display cumulative effects of
interactions. We used SHAP feature importance to describe the top 10 predictive features of non-cancer related
total healthcare cost 12-24 months after incident prostate cancer diagnosis. SHAP summary and partial density
plots for key variables were used to illustrate non-linear relationships between important features and noncancer related total healthcare cost.
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XGBoost hyperparameters can be adjusted to fine-tune regularization to control model complexity to
optimize predictive performance.(43)
Machine learning analyses were conducted using Python 3.7 with open-source scikit-learn 0.21.3
wrapper interface for XGBoost regressor.
TreeSHAP was used to generate SHAP and SHAP feature plots using Python 3.7 and the SHAP package
(0.29.2).
4.4 Results
Study cohort description
The study cohort was predominantly non-Hispanic white (81.3%) (Table 4.1). The median age at
diagnosis was 73.5 years and did not differ by year of diagnosis (2003-2009: M=73.8, SD= 5.4; 2010-2013: M=
73.2, SD=5.2). Overall 18.1% used CM, defined as no curative treatment within 12 months of incident localized
prostate cancer diagnosis.
Among older men with incident localized prostate cancer, 25.2% used LVC in the 12 months prior to
cancer diagnosis. Screening for asymptomatic carotid artery stenosis, Magnetic Resonance Imaging (MRI) for
low-back pain, and traction for low-back pain were the most frequently reported low-value care procedures.
Low-value care use counts ranged from 1 to 6, with 13422, 4105, and 5649 patients using 1, 2, or 3 or more LVC
services, respectively.
Cohort characteristics and Low-value care
Use of low-value care was significantly more common in older men aged 75 years or older, with
multimorbidity, with less than 10 years of life expectancy, and who used preventative care (Table 4.1). Use of
any low-value care was lower among patients using CM (15.2%), with MRI for low-back pain, traction for lowback pain, and asymptomatic carotid artery stenosis more frequent among patients using treatment
(Supplemental Table 4.2).
Predictive feature importance of low valve care
The predictive feature importance for low-value on healthcare expenditures ranked 7th (Figure 4.1).
Absence of low-value care was inversely associated with healthcare expenditures, with a complex linear
increase for every additional low-value care service used (Figure 4.2).
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Statistical Associations of Low-value care to healthcare expenditures
Average outpatient, inpatient, “other”, and non-treatment related total healthcare expenditures were all
significantly higher in low-value care than in no low-value care use groups (Table 4.2). In adjusted models
using GLM with log-link function, every 1-unit increase in low-value care use was associated with an $858.82
increase in healthcare expenditures (Table 4.4).
Other Leading predictors of healthcare expenditures
Multimorbidity (physical condition count), care fragmentation, and conservative management use were
the top 3 predictors of healthcare expenditures with the highest absolute mean SHAP values (Figure 4.1).
Partial density plots display linear and complex relationships with healthcare expenditures (Figure 4.2). Lower
(0 to 1) and higher (>99) values of care fragmentation were inversely associated with healthcare expenditure
prediction (Figure 4.2). Physical health condition counts displayed more variation lower (0-4) versus higher
(>7) chronic condition counts (Figure 4.2). In contrast, CM use was inversely associated with healthcare
expenditure prediction (Figure 4.1).
Statistical Associations among other important features
Patients with a life expectancy of greater than 10 years had lower average healthcare expenditures
(M=$6941.96, SD=16028.12) versus 5-10 year (M=$12638.58±24002.64) and less than 5 year
(M=$21284.75±34633.97) life expectancy groups (M=$8893.27 ±19802.73) (F=1618.68, p<0.001). Healthcare
expenditures were also significantly lower among patients using CM (M=$7332.74 ± 18787.79) versus patients
without CM use (M= $9237.09 ± 20003.22) (p<0.001).
CM use was associated with a $932.05 decrease in non-treatment related total healthcare expenditures
versus treatment for low risk prostate cancer (Table 4.4). Life expectancies less than 10 years were associated
with significantly higher, and CM use, significantly lower, non-treatment related healthcare expenditures in
adjusted GLM models (Table 4.3).
4.5 Discussion
In this study, we used claims-based algorithms supported by expert consensus to identify low-value
care use prior to incident prostate cancer diagnosis. We observed that 1 in 4 older men with incident prostate
cancer used low-value care prior to diagnosis and that low value care use was associated with higher healthcare
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expenditures, defined as total non-cancer related healthcare expenditures 12- 24 months after incident prostate
cancer diagnosis.
Low-value care use prior to incident prostate cancer diagnosis was also associated with substantial increases in
healthcare expenditures. On average, older patients using low-value care before an incident localized prostate
cancer diagnosis were more likely to use treatment (versus CM) and to have higher healthcare expenditures.
These associations remained robust after adjustment for prostate cancer-specific life expectancy estimates,
low-risk prostate cancer, and practice ecosystem factors such as physician supply and care fragmentation,
suggesting that low-value care was a significant driver of cost within 2 years of diagnosis.
Efforts to promote a high-value, patient-centered healthcare system has led to increased attention on
excessive spending on low-value care, under-provision of high-value care, and policy approaches to controlling
the rising cost of cancer care. Recently, the Centers for Medicare & Medicaid Services (CMS) developed an
Oncology Care First Model that establishes performance based payment components based on prospective
total cost of care targets among patients completing curative treatment. As portions of cancer care
reimbursement are transitioned from fee-for-service (FFS) to capitation payments, identifying the most
important features of cost prediction could help providers establish more effective policies and interventions
for high cost patients. Up-stream, low-value care, such as PSA screening for men over age 70, are known to
contribute to increased short- and long- term costs associated with subsequent biopsies, treatment, and/or
additional PSA tests. We found that other non-cancer related low-value care procedures were predictive of
downstream expenditures after incident prostate cancer diagnosis. Our results have important implications for
predicting patient cost after incident care diagnosis, given that low-value care use prior to incident prostate
cancer diagnosis is predictive of higher cost.
CM use, defined as no treatment within one year post diagnosis (102), was one of the highest ranking
features in predicting healthcare expenditures using machine learning models. Previous studies report that CM
use, including both Active Surveillance and Watchful Waiting, could reduce annual healthcare costs associated
with avoidable localized prostate cancer treatment by an estimated 1.2 billion dollars.(64) Other studies have
reported 3 year median costs of $1914 and $10588 associated with CM versus low-value treatment,
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respectively.(32) We found that CM use was associated with a $1905 reduction in 12-24 month healthcare
expenditures independent of treatment-related costs.
High level evidence supports CM for localized prostate cancer among men with low-risk disease and/or
limited life expectancy to reduce overtreatment morbidities and excessive healthcare expenditures. Regardless
of initial treatment modality, incident prostate cancer patients encounter significant ephemeral anxiety that
predisposes patients to treatment without prostate cancer specific mortality benefit.(94) Decisional conflict,
adverse mental health effects, and survival expectations (103) associated with diagnosis are independent
factors associated with treatment selection regardless of risk grouping or comorbidity burden.(27) Other
studies report cascades of downstream care associated with avoidable treatment-related morbidities,
competing demand for chronic condition management and preventative care, and compounding costs. (21) We
speculate that an incident localized prostate cancer diagnosis among patients using low-value care services may
affect other forms of overtreatment or use of unnecessary care leading to higher cancer survivorship costs.
Older adults with multimorbidity, living in an urban locality, and/or specialist dense regions are at risk
for low-value care and down-stream cascades of high cumulative costs.(21) Patients with incident prostate
cancer and multimorbidity are likely to encounter additional care fragmentation, which may include
consultation from medical, urological, radiation, and/or surgical oncologists. Care fragmentation during
prostate cancer survivorship is associated with redundant use of healthcare services, PSA testing, and
proportional increases in cost.(24) As in previous studies, we found care fragmentation and multimorbidity
prior to incident prostate cancer diagnosis to highly ranked predictors of long term healthcare expenditures.
Current Oncology Care Model (OCM) do not address care complexities associated with multimorbidity,
care fragmentation, or non-treatment approaches to localized prostate cancer survivorship. Although
multidisciplinary approaches have been proposed as a management strategy for prostate cancer survivors, it
remains unclear how primary care and oncology professionals can effectively coordinate care in a fragmented
FFS environment. More research is needed to identify predictors of high cost consumption of care in order to
inform population health management initiatives and allow policymakers to develop tailored interventions to
proactively address high-cost patients.
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4.6 Strengths and Limitations
Despite calls to identify low-value care use in vulnerable populations, no studies have investigated how
use of low-value care in men with incident localized prostate cancer is associated with longer term survivorship
costs. We used previously validated algorithms to identify conservative management use, prostate cancer
specific mortality index, care fragmentation, and multimorbidity estimates to understand the predictive
importance of low-value care use on healthcare cost during survivorship. We also estimated non-treatment
related total expenditures 12-24 months after diagnosis to identify long-term costs lacking characterization in
the current literature. We applied statistical, machine learning, and novel machine learning interpretative
approaches to estimate and predict the impact of low-value care use on healthcare expenditures.
Our results must be interpreted with important limitations. First, this observational study is a claimsbased, retrospective analysis, therefore, our results are subject to unobservable variable bias and selection bias
of paid Medicare claims. To minimize the proportion of missed claims we included beneficiairies only
continously enrolled in Medicare (A&B, without HMO) throughout the study period. Second, our analysis may
not be generaliable to commerical insurance beneficiaries as we only observed Medicare FFS beneficiairies.
Our estimates of low-value care use are likely underestimated as methods for identification of low value care in
claims data are limited. Social determinants of health (i.e., income, education) were not available at the
individual level therefore county level measures were used. We only included measures detectable within a one
year period to match the length of the baseline period before diagnosis, likely leading to further
underestimation of costs. Although NCCN guidelines recommend CM for patients with low-risk cancer and a
life expectancy of less than 10 years, both curative therapies and Active Surveillance are evidenced-based
choices for patients with a life expectancy of greater than 10 years.(6) Lastly, we did not account for follow-up
costs such as PSA and/or biopsy procedures that are commonly part of routine medical practice for patients
using Active Surveillance and/or treatment related monitoring.
4.7 Conclusion
In this study, incremental use of low-value healthcare showed a significant positive association with
long-term, non-treatment related costs after adjustments for multiple possible confounders. Use of evidencebased CM after diagnosis was associated with lower non-treatment related total healthcare costs. Using
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machine learning, we estimate both low-value care and CM use to be high-ranking features of cost prediction
12-24 months after incident prostate cancer diagnosis. Targeting patients with low-value care use prior to
cancer diagnosis using existing claims data could help to reduce low-value care related morbidities by
proactively identifying high-cost patients.
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Table 4.1 Patient Characteristics by Low-value Care Use among Fee-for-Service Medicare Beneficiaries with
Incident Localized Prostate Cancer using Linked SEER Cancer Registry, 2005-2014 (n=75671)
LVC
No LVC
N
%
N
%
Χ2
p-value
19,071

ALL

25.2

56,600

73.3

Age in Years
66-74

12075

24.4

37474

75.6

75+

8135

31.1

17987

68.9

Race
White

16701

27.1

44853

72.9

Black

2079

24.1

6533

75.9

Hispanic

352

27.5

927

72.5

Other

1025

25.4

3014

74.6

Marital Status
Married

1271

24.7

3881

75.3

Unmarried

13908

26.5

38585

73.5

Separated/Divorced/Widowed

2495

26.3

7002

73.7

Unknown

2536

29.7

5993

70.3

Income quintiles
First

3746

25.5

10938

74.5

Second

3841

26.0

10912

74.0

Third

3909

26.5

10860

73.5

Four

3992

27.1

10726

72.9

Fifth

4283

28.4

10785

71.6

Education quintiles
First

4184

28.4

10545

71.6

Second

4062

27.4

10748

72.6

Third

3962

26.7

10890

73.3

Four

3872

26.1

10941

73.9

Fifth

3712

25.0

11146

75.0

Urologist density quintiles
First

3809

25.3

11262

74.7

Second

4265

27.7

11114

72.3

Third

3889

26.9

10562

73.1

Four

4349

28.0

11206

72.0

400.79

<0.001

39.00

<0.001

52.97

<0.001

38.85

<0.001

51.10

<0.001

49.73

<0.001

Fifth
3880
25.7 11231
74.3
Note: Based on 75671 older (age >66 years) Fee-for-Service Medicare beneficiaries, with continuous enrollment
in Medicare part A & Part B, diagnosed with incident localized prostate cancer between 2005 and 2014.
SEER= Surveillance, Epidemiology and End Results cancer Registry, CM= Conservative management.
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continued Table 4.1
Radiation oncologist quintiles

202.91

First

3773

24.5 11641

Second

4239

29.0 10365 71.0

Third

3739

25.2 11071

Four

4667

29.9 10960 70.1

75.5
74.8

Multimorbidity

6466.74 <0.001

0-2 Chronic conditions

4052 12.1

29314

87.9

>2 Chronic conditions

16158 38.2 26147

61.8

Prostate Cancer Comorbidity Index

5992.61 <0.001

10 or more years life expectancy

11676 20.2 46207 79.8

5-10 years life expectancy

5290 42.6 7140

57.4

5 or less years life expectancy

3244

39.5

60.5 2114

Conservative management
Conservative management use

3070 22.5 10592 77.5

No conservative management use

17140 27.6 44869 72.4

Preventative A1c test
A1c test

3604 35.9 6442

No a1c test

16606 25.3 49019 74.7

152.88

<0.001

497.32

<0.001

64.1

Preventative flu

644.46 <0.001

Influenza vaccination

9630 31.7

No influenza vaccination

10580 23.4 34705 76.6

20756 68.3

Preventative lipid screen
Lipid test

6270

No lipid test

13940 25.4 40941 74.6

Metro county

17337 27.2 46301 72.8

Non-metro county

2855

23.9 9074

<0.001

60.93

<0.001

115.28

<0.001

166.45

<0.001

76.1

SEER Region
Northeast

4499 29.0 11020

71.0

South

5018

25.9 14345

74.1

North Central

2533

29.6 6030

70.4

West

8160

25.3 24066 74.7

Year of diagnosis
9651

146.13
30.2 14520 69.8

Metro

<2009

<0.001

29.1

23567 70.9

≥2009
10559 24.9 31894 75.1
Note: Based on 75671 older (age >66 years) Fee-for-Service Medicare beneficiaries, with continuous enrollment
in Medicare part A & Part B, diagnosed with incident localized prostate cancer between 2005 and 2014.
SEER= Surveillance, Epidemiology and End Results cancer Registry, CM= Conservative management.
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Table 4.2 Healthcare Expenditures by Low-value Care Use among Elderly Fee-for-Service Medicare
Beneficiaries with Incident Localized Prostate Cancer SEER-Medicare, 2005-2014 (n=75671)
LVC
No LVC
n=19071
n=56600
Mean (SD)

Mean (SD)

Total healthcare expenditures 12589.57 (24028.45) 7647.83 (17988.73)

CI

p-value
<0.001
<0.001
<0.001

Outpatient expenditures

6467.20 (8740.10)

4063.00 (6110.23)

8752.17, 9034.37
4619.42, 4718.42

Inpatient expenditures

5276.75 (18032.29)

3114.84 (13664.18)

3553.42,3765.97

Other expenditures
845.69 (2996.22)
469.98 (2120.18)
547.74, 803.17
<0.001
Note: Based on 75671 older (age >66 years) Fee-for-Service Medicare beneficiaries, with continuous enrollment
in Medicare part A & Part B, diagnosed with incident localized prostate cancer between 2005 and 2014.
Healthcare expenditures for patients completing curative treatment (i.e., “No CM”) do not include treatment
costs. CI= Confidence interval, SEER= Surveillance, Epidemiology and End Results cancer Registry, CM=
Conservative management.
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Table 4.3. Healthcare Expenditures by Conservative Management Use among Elderly Fee-forService Medicare Beneficiaries with Incident Localized Prostate Cancer SEER-Medicare, 2005-2014
(n=75671)
CM
No CM
n=13662
n=62009
Mean (SD)

Mean (SD)

p-value

Total healthcare expenditures

7332.74 (18787.79)

9237.09 (20003.22)

Outpatient expenditures

3681.65 (7334.92)

4886.44 (6840.01)

<0.001
<0.001

Inpatient expenditures

3111.29 (13781.13)

3780.53 (15151.8)

<0.001

Other expenditures
539.8 (2438.32)
570.16 (2363.56)
Note: Based on 75671 older (age >66 years) Fee-for-Service Medicare beneficiaries, with continuous enrollment
in Medicare part A & Part B, diagnosed with incident localized prostate cancer between 2005 and 2014.
Healthcare expenditures for patients completing curative treatment (i.e., “No CM”) do not include treatment
costs. CI= Confidence interval, SEER= Surveillance, Epidemiology and End Results cancer Registry, CM=
Conservative management.
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Table 4.4 Parameter estimates of PCCI categories from unadjusted and adjusted generalized linear models
on 12-24 months healthcare expenditures among elderly Medicare fee-for-service beneficiaries with incident
localized prostate cancer diagnosis using SEER-Medicare data, 2005-2015 (n=75671).
Parameter
Parameter
Change #
Change #
Estimate (SE)
Estimate (SE)
Unadjusted GLM
Adjusted GLM
Age
66-74

8.949 (0.010)

7700.19

8.416 (0.055)

$4518.79

75 and over

0.370 (0.017)

3447.64

0.247 (0.018)

$1266.07

Prostate cancer
comorbidity score
10 or more years

8.845 (0.009)

6939.60

8.416 (0.055)

$4518.79

Less than 5 years

1.120 (0.031)

14329.27

0.895 (0.033)

$6540.21

Between 5 and 10 years

.599 (0.022)

5692.54

0.470 (0.023)

$2711.25

No

9.131 (0.009)

7331.97

8.416 (0.055)

$4518.79

Yes

-0.231 (0.021)

-1905.28

-0.219 (0.022)

$-932.05

8.956 (0.009)

7754.28

8.416 (0.055)

$4518.79

0.312 (0.013)

2839.27

0.174 (0.012)

$858.82

No

9.141 (0.010)

9320.77

8.416 (0.055)

$4518.79

Yes

-.140 (0.017)

-1217.68

-0.023 (0.018)

NS

Conservative management

Low-value care1
Total Low-value care
Low-risk prostate cancer

Care fragmentation
.010 (0.000)
52.87
.006 (0.00)
$27.19
Note: Based on 75671 older (age >66 years) Fee-for-Service Medicare beneficiaries, with continuous enrollment
in Medicare part A & Part B, diagnosed with incident localized prostate cancer between 2005 and 2014.
Healthcare expenditures for patients completing curative treatment (i.e., “No CM”) do not include treatment
costs. Total healthcare expenditures include inpatient, outpatient, durable medical equipment, and home
health agency costs with treatment-related cost subtracted.
1. Sum of low-value care procedures in 12 months before prostate cancer diagnosis.
Change # was calculated by difference between the 1) exponentiation of the model intercept term and 2) the
sum of the intercept and the variable parameter estimate.
Compare to omitted category
SE= Standard Error, SEER= Surveillance, Epidemiology and End Results cancer Registry, CM= Conservative
management.
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Figure 4.1 SHAP Feature Importance and Summary Plot of Low-value Care and Conservative Management
Use on Non-Treatment Related Total Healthcare Expenditures among Fee-for-Service Medicare Beneficiaries
with Incident Localized Prostate Cancer using Linked SEER Cancer Registry, 2005-2014 (n=75671)

A.

B.

(A) Mean SHAP values and (B) SHAP summary plot in descending order of log-dollars. Based on 75671 older
(age ≥ 66 years) Fee-for-Service Medicare beneficiaries, with continuous enrollment in Medicare Part A & Part
B, diagnosed with incident localized prostate cancer (Stage ≤T2a) between 2005 and 2014.
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Figure 4.2 SHAP Partial Density Plots of Selected Features on Non-Treatment Related Total Healthcare
Expenditures among Fee-for-Service Medicare Beneficiaries with Incident Localized Prostate Cancer using
Linked SEER Cancer Registry, 2005-2014 (n=75671)
A.

C.

B.

D.

SHAP Partial Dependence plots (PDP) of SHAP values (log-dollars) values by (A.) Multimorbidity (Physical
conditions only), (B.) Care fragmentation, (C) Low value care total prior to incident prostate cancer diagnosis,
and (D.) Conservative Management. Based on 75671 older (age ≥ 66 years) Fee-for-Service Medicare
beneficiaries, with continuous enrollment in Medicare Part A & Part B, diagnosed with incident localized
prostate cancer (Stage ≤T2a) between 2005 and 2014.
Physical condition total = Total count of multimorbidity physical conditions.
Care fragmentation = Bice-Boxerman continuity of care index to calculate care fragmentation during the 12
month baseline period (See Methods).
Low value care = Sum of low value care prior to incident prostate cancer diagnosis.
Conservative Management = Yes (1)/No (0).
SHAP = Shapley Additive ePlanations.
SEER= Surveillance, Epidemiology, and End Results cancer Registry.
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Chapter 5
5 Summary and Conclusion
5.1 Summary of Findings and Discussion
The goal of this dissertation is to highlight healthcare practices that provide limited clinical benefit,
potentially harmful effects, and a significant economic burden among older men with incident localized
prostate cancer. This dissertation also highlights the role of patient experiences in receiving high value care for
incident prostate cancer. Older men with localized prostate cancer represent a large, medically complex and
growing population. Although prostate cancer is heterogeneous at the population level, high-level randomized
evidence concluded a lack of significant survival benefit of treatment (surgery, radiation, chemotherapy,
hormone therapy, cryotherapy) among men with intermediate grade disease and 15 year life expectancy.(104–
106) Conservative management (Active Surveillance and Watchful Waiting) within the context of cancer risk
group, life expectancy estimates, and personal values has been promoted as high-value care as significant
quality decrement and high costs of overtreatment can be avoided. Despite evidence-based guidelines
recommending conservative management for a decade, many men with low-risk prostate cancer and limited
life expectancy received treatment for prostate cancer. Higher rates of treatment use among fee-for-service
(58%) versus integrated healthcare beneficiaries (20%) highlight disparities in evidenced-based healthcare
delivery.
This dissertation focused on three related studies: 1) examine the leading predictors of low-value
healthcare practice (i.e., prostate cancer treatment for low-risk prostate cancer) among older men; 2) assess the
role of patient‐reported experience with care on high-value prostate cancer management; and 3) Estimate the
association of high-value care on non-cancer related healthcare expenditures. In all of these studies an
emphasis is placed on multimorbidity because of high prevalence and negative clinical, humanistic, and
economic effects throughout cancer survivorship. We specifically examined the associations of patient‐reported
experiences with evidence-based treatment selection and low-value care to reflect the standards of the Institute
of Medicines (IOM) and The National Quality Task Force aim to promote patient-centered care and reductions
in inappropriate, wasteful healthcare practices among adults managing chronic conditions.(15,16)
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This dissertation filled a knowledge gap through a comprehensive analysis of clinical and non-clinical
factors that drive low-value cancer treatment among incident low-risk prostate cancer. A novel feature of this
dissertation is the use of machine learning algorithms and the application of model agnostic interpretable
machine learning techniques. This dissertation also made a unique contribution and clarified the role of life
expectancy on the complex decision making process of choosing from several treatments (surgery, radiation,
cryotherapy, and or chemotherapy and hormone therapy) or conservative management. We distinguished
between comorbidity and life expectancy to estimate the independent contribution of life expectancy on
treatment choice. This dissertation is a series of firsts for its measurement of care fragmentation during cancer
survivorship, use of machine learning algorithms and unlocking the “black box” prediction with interpretable
machine learning techniques, and assessing the role of patient-reported experiences on high-value care among
older men with incident prostate cancer.
5.2 Implications and Suggestions for Future Research
A common theme that emerged from our studies is the negative effect of multimorbidity on outcomes
(i.e., low-value cancer treatment, high-value conservative management, and non-cancer related healthcare
expenditures). This finding is not surprising given the voluminous data and robust evidence on the negative
health effects of multimorbidity on health outcomes in a variety of settings and populations. Adults with
multimorbidity and incident cancer are at high-risk for poor quality of both cancer and non-cancer care
(37,107) as current non-cancer clinical guidelines are developed within a single-disease framework.(108) Men
with multimorbidity and incident cancer may not opt for conservative management because of a preference for
immediate cure (ie, “take care of it”)(87) and may have a preference to avoid one more condition that requires
long‐term management. In addition, men are likely to experience fear of non-treatment regret,(88) emotional
distress,(89) and anxiety.(90) The implementation of OCM which provides a bundled payment for all care
during an episodic treatment will inherit the complex management requirements of men with multimorbidity
and incident prostate cancer. Value-based payment mechanisms are needed to support the conservative
management of incident localized prostate cancer with multimorbidity, especially among men with limited life
expectancy, who benefit more from non-cancer chronic condition management versus curative treatment and
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other potential cascades of low-value care or increased care fragmentation without the benefit of reduced
prostate cancer specific mortality.
Our results suggest focusing on reducing care fragmentation, such as broader system reforms to
increase care continuity between primary care physicians and oncologists, could help reduce treatment
selection among patients with low-risk prostate cancer. Considering our results, we speculate that care
fragmentation is likely to contribute to differing treatment rates for low-risk prostate cancer between Medicare
FFS and Veterans Administration beneficiaries (approximately 37%).(46)
For a subset of individuals older men with localized prostate cancer we observed that patient
experiences with timely care was important in treatment choice. Timely access to care for men with localized
prostate cancer is not limited to initial diagnosis of prostate cancer, but the opportunity and ease by which a
patient is able to access and utilize needed services along the continuum of care throughout survivorship.(93)
Choices for elderly localized prostate cancer patients involve selecting curative and non-curative treatments
with trade‐offs in efficacy, potential adverse quality of life effects, and competing risk mortality. Timeliness of
care domains used in this dissertation, such as perceived barriers to appointment scheduling, are fundamental
to shared decision‐making among multiple health‐care providers that significantly influence treatment choice
for men with localized prostate cancer.(94–96) We speculate that adults with higher timely care ratings may
choose CM if they have a favorable perception of health‐care system capacity to provide services once a need is
detected. Our results suggest that addressing specific modifiable barriers to timely care along the cancer
continuum for older adults with localized prostate cancer and limited life expectancy could reduce the adverse
effects of overtreatment on health outcomes and costs.
A noteworthy finding is the superior performance of machine learning algorithms over traditional
statistical models, specifically logistic regression. This dissertation confirmed flexibility, predictive accuracy,
and ability of machine algorithms to handle multicollinear variables. With machine learning, model
misspecification can be avoided through the use of cross-validation model tuning on “training” data before
applying the algorithm to a “test” or new data set. Once validated, interpretable machine learning approaches,
such as SHAP, can be applied to reveal the complexity and non-linearity of associations using feature
importance and SHAP summary and partial density plots. In our dissertation, machine learning analyses
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revealed significant variation among individuals (i.e. patient-level) of estimated outcomes at specific feature
values. Our results highlight the need to target individuals with non-linear, complex feature combinations
pushing them toward low-value outcomes that are otherwise unobservable with “on average'' traditional
statistical approaches.
The application of machine learning algorithms to predict low- and high- value care are in alignment
with the National Quality Forum created a Technology Evaluation Framework.(16) These organizations
promote the use of advanced technologies, such as machine learning algorithms, to identify solutions to
address high-value healthcare practices. The framework seeks to strengthen health literacy to complement
shared decision making processes to facilitate evidence-based medicine while reducing propensity for lowvalue services. Our study demonstrates that machine learning and interpretive approaches can be leveraged to
proactively identify patients who may benefit from interventions, for both patients and physicians, to facilitate
shared decision making regarding prostate cancer care and reduce the use of low-value care.
Our results from the analysis on the association of low- and high- value care to non-cancer related
healthcare expenditures suggest the development and implementation of targeted payment reforms could
reduce the economic burden to the payers, specifically Medicare. Current Oncology Care Model (OCM) are
voluntary five-year bundled payment programs developed by the Center for Medicare & Medicaid Innovation
(CMMI) to facilitate high-value, lower-cost healthcare through improved care coordination and episodic or
bundled reimbursement. OCM incentivizes providers to lower the total cost of care for patients throughout the
treatment episodes.(109) Although multidisciplinary approaches have been proposed as a management
strategy for prostate cancer survivors, it remains unclear how primary care and oncology specialist delivery
coordinated care in a fragmented FFS environment. Our research highlights how the application of machine
learning can be used to identify patients at risk of low-value care. Healthcare entities can leverage large patient
data sets, claims registries, and electronic medical records to continuously re-train machine learning models to
improve predictive accuracy and provide personalized medicine for many diseases. However, the
implementation of such technologies will require a robust technical investment from healthcare entities to
develop specific algorithms for the patient population they serve. Policy makers should consider mechanisms
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to support healthcare organizations in the development of predictive “precision” population health
technologies.
5.3 Strengths and Limitations
Our dissertation was a series of many first. We used both multimorbidity and prostate cancer-specific of
life expectancy measures to understand the independent contributions of comorbidity and prostate cancer
specific mortality on treatment selection among men with localized prostate cancer. We used robust machine
learning and statistical methods to explore novel predictive and statistical associations of low-value care,
patient-reported experience measures, and care fragmentation on overtreatment and cost outcomes among
older adults with multimorbidity. Our research supports nationally recognized strategic objectives for
improving patient-centered care while identifying predictors to reduce inappropriate low-value care. We used
cancer registry, claims, MCAHPS surveys, and other socio-demographic data linkages to incorporate measures
of multimorbidity, care fragmentation, patient-reported experience measures, social determinants of health,
and low-value care in machine learning and statistical models. Although educational attainment may not be
modifiable among older adults, initiatives such as “health in all policies'' by the World Health Organization and
the Centers for Disease and Prevention Control suggest the integration and consideration of community health
policy(73) as social, economic, and physical environments have a significant impact on the health of an
individual. With these considerations, we developed machine learning and statistical approaches using a
competing demands framework in all of our study aims.
Due to the retrospective nature of this work our findings are not causal. Generalizability to younger
patients, health Maintenance Organization, and integrated healthcare networks may not be appropriate as our
studies included only fee-for-service beneficiaries. Measurement of low-value care in claims data requires the
estimation of clinical scenarios using inclusion and exclusion criteria that are diagnosis and/or procedure
specific, and often include a temporal component. We could only select procedures meeting criteria for lowvalue care that could be operationalized accurately in claims data, therefore, we are likely to underestimate the
burden of low-value care.
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5.5 Conclusion
Our studies reveal that low-value cancer treatment is highly-prevalent as only 2 in 5 men received
conservative management. In predictive models of low-value care (i.e., overtreatment) and high-value care
(i.e., conservative management) we did not find a life expectancy of 10 or more years to be predictive. These
results indicate that treatment choice among older adults, within the context of life expectancy, do not reflect
evidence-based guidelines for prostate cancer treatment. Our findings suggest a need for broad
implementation of interventions to improve patient and physician education during the shared-decision
process.
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Supplemental Figure 7.1 Feature Importance of Treatment Prediction among Fee-for-Service
Medicare Beneficiaries with Incident Low-risk Prostate Cancer using SEER Cancer Registry,
2009-2014 (n=13870)

Mean SHAP values in descending order of log-odds. Based on 13870 older (age ≥ 66 years) Fee-for-Service
Medicare beneficiaries, with continuous enrollment in Medicare Part A & Part B, diagnosed with incident lowrisk prostate cancer (Gleason 6, PSA <10, Stage ≤T2a) between 2009 and 2014.
Age group included 66-74 and 75 and over categories.
Care fragmentation = Bice-Boxerman continuity of care index to calculate care fragmentation during the 12
month baseline period (See Methods).
SEER= Surveillance, Epidemiology, and End Results cancer Registry.
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Appendix 7.2 Unadjusted and Adjusted Odds Ratios and 95% Confidence Intervals (CI) of PCCI, Mental
Health, Timeliness of Care, Low-risk Prostate Cancer, and Education on Conservative Management Use in
among Fee-for-Service Medicare Beneficiaries with Incident Localized Prostate Cancer using Linked SEER
Cancer Registry with MCAHPS, 2002-2013 (N = 496).
UOR [95% CI]
p-value
AOR [95% CI]
p-value
Prostate Cancer Comorbidity Index
5 to 10 years life expectancy

0.58 [0.38 - 0.90]

0.014

0.48

[0.29 - 0.78]

0.003

< 5 years life expectancy

0.58

[0.33 - 1.03]

0.062

0.42

[0.21 - 0.83]

0.012

1.15

[1.05 - 1.27]

0.003

1.20

[1.09 - 1.34]

0.001

1.41

[0.95 - 2.08]

0.088

1.65

[1.07 - 2.58]

0.024

2.97

[1.50 - 5.90]

0.002

5.54

[2.33 - 13.2]

0.001

College or more

2.49

[1.30 - 4.78]

0.006

3.28

[1.52 - 7.10]

0.002

High-school graduate

2.41

[1.18 - 4.92]

0.015

3.57

[1.60 - 7.96]

0.002

> 10 years life expectancy (Ref.)
Getting Care Quickly
Low-risk prostate cancer
Yes
No (Ref.)
Mental Health
Fair/Poor
Excellent/Very Good (Ref.)
Education

No high-school grad. (Ref.)
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Appendix 7.3 Unadjusted and Adjusted Odds Ratios and 95% Confidence Intervals of PCCI,
Multimorbidity, Mental Health, Timeliness of Care, Low-risk Prostate Cancer, and Education on
Conservative Management Use up to 24 Months after Incident Prostate Cancer among Fee-for-Service
Medicare Beneficiaries using Linked SEER Cancer Registry with MCAHPS, 2002-2013 (N = 496).
UOR [95% CI]

AOR [95% CI]

p-value

Multimorbidity Model
Multimorbidity
0.52

[0.35 - 0.77]

0.001

0.42

[0.27 - 0.65] <0.001

1.13

[1.02 - 1.24]

0.014

1.21

[1.09 - 1.35]

<0.001

1.46

[0.97 - 2.18] 0.068

1.76

[1.14 - 2.72]

0.01

3.44

[1.73 - 6.81] <0.001

4.32

[1.86 - 10.1]

<0.001

College or more

2.76

[1.35 – 5.65] 0.006

3.21

[1.50 – 6.89]

0.003

High-school graduate

3.06

[1.42 – 6.63] 0.004

3.53

[1.59-7.83]

0.002

Yes
No (Ref.)
Getting Care Quickly
Low-risk prostate cancer
Yes
No (Ref.)
Mental Health
Fair/Poor
Excellent/Very Good (Ref.)
Education

No high-school graduation (Ref.)
PCCI Model
Prostate Cancer Comorbidity Index
5 to 10 years life expectancy

0.52

[0.33 – 0.82] 0.005

0.39

[0.30 - 0.70] <0.001

< 5 years life expectancy

0.56

[0.31 – 1.01] 0.056

0.34

[0.16 – 0.73]

0.005

Getting Care Quickly

1.20

[1.08 - 1.34]

0.001

Low-risk prostate cancer

1.76

[1.11 – 2.79]

0.017

7.59

[3.07 – 18.8] <0.001

0.26

[0.11 – 0.60]

>10 years life expectancy (Ref.)

Yes
No (Ref.)
Mental Health
Fair/Poor
Excellent/Very Good (Ref.)
Education
High-school graduate

0.002

No high-school grad. (Ref.)
Note: Based on 496 older (age >66 years) Fee-for-Service Medicare beneficiaries, with continuous enrollment in Medicare
part A & Part B, diagnosed with incident localized prostate cancer between 2003 and 2013. Adjusted for age, race, marital
status, income, education, health status, urologist density, radiation oncologist density, SEER region, geography,
diagnostic year, and low-risk prostate cancer.
UOR= Unadjusted Odds Ratio, AOR= Adjusted Odds Ratio, N.S.= Not significant, CI= Confidence interval, Ref=
Reference group, SEER= Surveillance, Epidemiology and End Results cancer Registry, MCAHPS= Medicare Consumer
Assessment of Healthcare Providers and System surveys, CM= Conservative management, PCCI= Prostate Cancer
Comorbidity Index. Statistically significant results displayed.
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Appendix 7.4 Prostate cancer treatment codes used within 12 months of prostate cancer diagnosis to Identify
Conservative Management Use
55840, 55842, 55845, 55866, 55810, 55812, 55815 and 60.62, 17.42, 60.5, 60.4, and
Radical prostatectomy
60.3 (40.3, 40.53, and 40.59 for lymph node dissection)
76873, 55859, 76965, 55860, 55875, 55876, 76873, 76965, 77326, 77327, 77328,
77761, 77762, 77763, 77799, 77776, 77777, 77778, and 60.99, 92.27, 92.28, and
Brachytherapy
92.29, 77781, 77782, 77783, 77784, 77785, 77786, 77787, 77789, 77790, Q3001,
A9527, C1715, C1716, C1717, C1719, C1728, C2616, C2634, C2635, C2636, C2637,
C2638, C2639, C2640, C2641, C2642, C2643, C2698, C2699, C9725
77305, 77310, 77315, 77321, 77371,77372, 77373, 77402, 77403, 77404, 77406,
External Beam
77407, 77408, 77409, 77411, 77412, 77413, 77414, 77416, 77422, 77423, 92.24, 92.26,
Radiotherapy
77301, 77418, 0073T, 77380, 77381, 77520, 77522, 77523, and 77525, 77301,77338,
77761, 77762, 77763, 77789, 77427
Cryotherapy
50250, 50593, 55873, 55873, 60.62, C2618, G0160, G0161
J1050, J1051 (Progesterone),J1950 J9217 J9218 J9219, C9430 (Lupron), J9165
(DES), J9202 (Zoladex), J3315 (Trelstar), J9225 CPT 11981(Vantas), all injections
Androgen Deprivation
ICD-99.24, S0175 (Flutamide), J8999 (Bicalutamide/Flutamide/Nilutamide)
Therapy
S0165, J0128, C9216, (Abarelix), J9155 (Degarelix), S9560 (any hormone/adt),
G0356 (any ADT )
Conservative
No treatment within one year of prostate cancer diagnosis
management
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Appendix 7.5 Patient Characteristics by Conservative Management among Fee-for-Service Medicare
Beneficiaries with Incident Localized Prostate Cancer using Linked SEER Cancer Registry, 2005-2014
(n=75671)
CM
No CM
N
%
N
%
Χ2
p-value
13662

ALL

18.1

62009

82.0

Age in Years
66-74

8424

17.0

41125

83.0

75+

5238

20.1

20884

79.9

Race
White

10741

17.4

50813

82.6

Black

1941

22.5

6671

77.5

Hispanic

188

14.7

1091

85.3

Other

750

18.6

3289

81.4

Marital Status
Married

8190

15.6

44303

84.4

Unmarried

997

19.4

4155

80.6

Separated/Divorced/Widowed

2204

23.2

7293

76.8

Unknown

2271

26.6

6258

73.4

Income quintiles
First

2772

18.9

11912

81.1

Second

2620

17.8

12133

82.2

Third

2696

18.3

12073

81.7

Four

2558

17.4

12160

82.6

Fifth

2642

17.5

12426

82.5

Education quintiles
First

2604

17.7

12125

82.3

Second

2461

16.6

12349

83.4

Third

2496

16.8

12356

83.2

Four

2758

18.6

12055

81.4

Fifth

2984

20.1

11874

79.9

Urologist density quintiles
First

2509

16.6

12562

83.4

Second

2820

18.3

12559

81.7

Third

2689

18.6

11762

81.4

Four

2817

18.1

12738

81.9

Fifth

2798

18.5

12313

81.5

79

107.6

<0.001

145.2

<0.001

813.3

<0.001

35.5

<0.001

102.0

<0.001

33.0

<0.001

Continued Appendix 7.5
Radiation oncologist quintiles
First

2631

17.1 12783

82.9

Second

2421

16.6 12183

83.4

Third

2756

18.6 12054

81.4

Four

2960

18.9 12667

81.1

Fifth

2865

19.0 12247

81.0

Low-risk prostate cancer
GS >6 and/or PSA ≥10ng/mL

6245

12.8 42513

87.2

GS 6 and PSA <10ng/mL

7417

27.6 19496

72.4

Multimorbidity
0-2 Chronic conditions

7465

22.4 25901

77.6

>2 Chronic conditions

6197

14.6 36108

85.4

Prostate Cancer Comorbidity Index
10 or more years life expectancy

10780 18.6 47103

81.4

5-10 years life expectancy

1927

15.5 10503

84.5

5 or less years life expectancy

955

17.8 4403

82.2

Low-value care
Low-value care

3070

15.2 17140

No low-value care

10592 19.1 44869
1590

15.8 8456

No a1c test

12072 18.4 53553

<0.001

2600

<0.001

752.3

<0.001

67.6

<0.001

206.7

<0.001

38.8

<0.001

422.4

<0.001

84.8
80.9

Preventative A1c test
A1c test

58.18

84.2
81.6

Preventative flu
Influenza vaccination

4420

14.5 25966

85.5

No influenza vaccination

9242

20.4 36043

79.6

Preventative lipid screen

<0.001

Lipid test

3161

15.2 17629

84.8

No lipid test

10501 19.1 44380

80.9

Metro
Metro county

11586 18.2 52052

81.8

Non-metro county

2047

82.8

17.2 9882

SEER Region
Northeast

2137

13.8 13382

86.2

South

3296

17.0 16067

83.0

North Central

1370

16.0 7193

84.0

West

6859

21.3 25367

78.7

Year of diagnosis
<2009

6737
80

20.3 26481

79.7

14.2

<0.001

458.1

<0.001

198.4

<0.001

≥2009

6925

16.3 35528

83.7

Appendix 7.6 Low-value Care by Conservative Management Use among Fee-for-Service Medicare
Beneficiaries with Incident Localized Prostate Cancer using Linked SEER Cancer Registry, 2005-2014
(n=75671)
LVC
CM
No CM (n=62009)
(n=19071)
(n=13662)
N
LVC% N
CM% N
No CM % Χ2
p-value
Preoperative chest radiography
Yes
No
Preoperative echocardiography
Yes
No
Arthroscopic surgery for knee
osteoarthritis
Yes
No
Hypercoagulability testing for
patients with DVT
Yes
No
Stress echocardiography for CAD or
risk assessment
Yes
No
Laminectomy or spinal fusion
Yes
No
Fiberoptic laryngoscopy for
sinusitis
Yes
No
Routine monitoring of digoxin in
CHF patients
Yes
No
EEG or imaging monitoring in
patients with syncope
Yes
No
Serological tests for helicobacter
pylori
Yes
No

2010

2.66
280
13.9
13382 18.2

1730
60279

33

**
**

348

14.8
18.1

15.5
18.1

17.8
18.1

293
61716

81

14.8
18.1

0.102

0.750

12.144

<0.001*

1.196

0.274

4.649

0.031*

2.731

0.098

0.064

0.800

5.442

0.020*

84.2
81.9

542
61467

85.2
81.9

518
61491

84.5
81.9

1141
82.2
60868 81.9

0.97
108
13554

0.181

85.0
81.9

1.83
247
13415

732

1628
60381

0.81
95
13567

1388

15.8
18.1

1.793

83.3
81.9

0.84
94
13568

613

65
61944

0.46
55
13607

636

15.0
18.1

<0.001*

**
**

2.53
288
13374

11.982
86.1
81.9

0.10
13
16.7
13649 18.1

1916

868
61141

0.04
**
**

78

13.9
18.1

<0.001*

86.1
81.8

1008 1.33%
140
13522

23.738

624
61385

85.2
81.9

MRI in individuals with traumatic
brain injury
Yes
No
Traction for low back pain
Yes
No
Screening for asymptomatic carotid
artery stenosis
Yes
No
Immunoglobulin (IgG, IgE) tests
for evaluation of allergy
Yes
No
MRI Lumbar Spine for Low Back
Pain
Yes
No
IVC filters to prevent PE
Yes
No
Renal angioplasty or stent
Yes
No
Vitamin D screening
Yes
No
Head imaging for uncomplicated
headache
Yes
No
Imaging for plantar fasciitis
Yes
No

16

0.02
**
**

5759

16.4
18.1

41

43

<0.001*

1.444

0.230

84.8
81.9

897
12765

15.6
18.3

4862
57147

84.4
81.7

**
**

**
**

**
**

**
**

0.05

0.06
**
**

**
**

15.2
18.1

392
61617

82

**
**

**
**

1.201

0.273

2.648

0.104

0.018

0.893

0.516

0.473

82.2
81.9

0.05
**
**

0.808

84.8
81.9

0.44
273
61736

0.059

**
**

0.61

59
17.8
13603 18.1
37

228
61781

65.614

25.889 <0.001*

70
13592
332

15.2
18.1

0.016*

85.4
81.6

7.61

**
**
462

6291
55718

5.850
83.6
81.9

0.36
41
13621

5759

2596
59413

0.942

**
**

9.74
1076
14.6
12586 18.4

269

**
**

7.61
510
13152

7367

**
**

0.005

**
**
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Appendix 7.8 Aim 1 python codes

import pandas as pd
import numpy as np
feature_names for SHAP analyses below
feature_names = [ "Married", "Age group 66-74", "Median income", "Care fragmentation", "Less than
highschool education", "College education", "SEER Northeast", "Primary Care visit", "Urologist density",
"Influenza vaccination", "SEER West", "Multimorbidity group", "A1c screening", "Lipid screening", "Bone
density screening", "Psyhcology visit", "Life expectancy over 10 years", "Hispanic", "White race", "Black race",
"Metro locality", "SEER South", "SEER Northcentral", "Separated/Divorced/Widowed","Unmarried", "Low
value care (sum)", "Radiation Oncologist density", "Diagnostic year 2009", "Diagnostic year 2010", "Diagnostic
year 2011", "Diagnostic year 2012", "Diagnostic year 2013", "Diagnostic year 2014" ]
use the list to select a subset of the original DataFrame
X = dataset[feature_names]
print the first 5 rows
X.head()

#Instantiate Y with dependent/label var, X with indepdent/feature vars
y = dataset['trmt']
#Split data into train and test data sets; 80/30
from sklearn.model_selection import train_test_split
X_train, X_test, y_train, y_test = train_test_split (X, y, test_size = 0.30, random_state=21)
from collections import Counter
# count # of examples in each class
counter = Counter(y)
# estimate scale_pos_weight value, assuming the class labels are 0 and 1. Modify according to your
use-case
weight = counter[0] / counter[1]
Calibration before tune

from sklearn.calibration import CalibratedClassifierCV
import seaborn as sns
fig, ax = plt.subplots(1, figsize=(12, 6))
# Create an uncorrected classifier.
clf = xgc
clf.fit(X_train, y_train)
y_test_predict_proba = clf.predict_proba(X_test)[:, 1]
fraction_of_positives, mean_predicted_value = calibration_curve(y_test, y_test_predict_proba, n_b
ins=10)
plt.plot(mean_predicted_value, fraction_of_positives, 's-', color='red', label='Uncalibrated')
# Create a corrected classifier.
clf_sigmoid = CalibratedClassifierCV(clf, cv=3, method='sigmoid')
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clf_sigmoid.fit(X_train, y_train)
y_test_predict_proba = clf_sigmoid.predict_proba(X_test)[:, 1]
fraction_of_positives, mean_predicted_value = calibration_curve(y_test, y_test_predict_proba, n_b
ins=10)
plt.plot(mean_predicted_value, fraction_of_positives, 's-', label='Calibrated (Platt)')
plt.plot([0, 1], [0, 1], '--', color='gray')
sns.despine(left=True, bottom=True)
plt.gca().xaxis.set_ticks_position('none')
plt.gca().yaxis.set_ticks_position('none')
plt.gca().legend()
plt.title("$XGClassifier$ Sample Calibration Curve", fontsize=20); pass
png

png
from sklearn.metrics import roc_auc_score, accuracy_score, recall_score, precision_score, f1_score,
cohen_kappa_score
# Performance for train
train_y_pred = clf_sigmoid.predict(X_train)
auc = roc_auc_score(y_train, train_y_pred)
print("AUC performance for train : ", auc)
# Calc bal_accuracy, recall, and average positive prediction score
recall = recall_score(y_train, train_y_pred)
print("Recall performance for train : ", recall)
f1 = f1_score(y_train, train_y_pred)
print("F1 performance for train : ", f1)
prcsn = precision_score(y_train, train_y_pred,labels=np.unique(train_y_pred))
print("Precision performance for train : ", prcsn)
# Performance for train
y_pred = clf_sigmoid.predict(X_test)
auc_t = roc_auc_score(y_test, y_pred)
print("AUC performance for test : ", auc_t)
# Calc bal_accuracy, recall, and average positive prediction score
recall_t = recall_score(y_test, y_pred)
print("Recall performance for test : ", recall_t)
f1_t = f1_score(y_test, y_pred)
print("F1 performance for test : ", f1_t)
prcsn_t = precision_score(y_test, y_pred,labels=np.unique(y_pred))
print("Precision performance for test : ", prcsn_t)
AUC performance for train : 0.6787989250338197
Recall performance for train : 0.9956783454236765
F1 performance for train : 0.8606497231672336
Precision performance for train : 0.7578712406015038
AUC performance for test : 0.5588647894037931
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Recall performance for test : 0.958139534883721
F1 performance for test : 0.8089412475456879
Precision performance for test : 0.6999477260846837
import xgboost as xgb # XGBoost
# Preliminary model w/o tuning or cross-validation
clf_xgb = xgb.XGBClassifier(objective='binary:logistic',scale_pos_weight=weight,
seed=42)
clf_xgb.fit(X_train,
y_train,
verbose=True,
## the next three arguments set up early stopping.
early_stopping_rounds=10,
eval_metric=['auc'],
eval_set=[(X_test, y_test)])

XGBClassifier(base_score=0.5, booster='gbtree', colsample_bylevel=1,
colsample_bynode=1, colsample_bytree=1, gamma=0, gpu_id=-1,
importance_type='gain', interaction_constraints='',
learning_rate=0.300000012, max_delta_step=0, max_depth=6,
min_child_weight=1, missing=nan, monotone_constraints='()',
n_estimators=100, n_jobs=0, num_parallel_tree=1, random_state=42,
reg_alpha=0, reg_lambda=1, scale_pos_weight=0.4955790381712314,
seed=42, subsample=1, tree_method='exact', validate_parameters=1,
verbosity=None)
# predict probabilities
xgb_probs = clf_xgb.predict_proba(X_test)
# keep probabilities for the positive outcome only
xgb_probs = xgb_probs[:, 1]
import matplotlib.pyplot as plt
prediction=xgb_probs
plt.figure(figsize=(15,7))
plt.hist(prediction[y_test==0], bins=50, label='Negatives')
plt.hist(prediction[y_test==1], bins=50, label='Positives', alpha=0.7, color='r')
plt.xlabel('Probability of being Positive Class', fontsize=25)
plt.ylabel('Number of records in each bucket', fontsize=25)
plt.legend(fontsize=15)
plt.tick_params(axis='both', labelsize=25, pad=5)
plt.show()
png

png
# Performance for train
train_y_pred = clf_xgb.predict(X_train)
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auc = roc_auc_score(y_train, train_y_pred)
print("AUC performance for train : ", auc)
# Calc bal_accuracy, recall, and average positive prediction score
recall = recall_score(y_train, train_y_pred)
print("Recall performance for train : ", recall)
f1 = f1_score(y_train, train_y_pred)
print("F1 performance for train : ", f1)
prcsn = precision_score(y_train, train_y_pred,labels=np.unique(train_y_pred))
print("Precision performance for train : ", prcsn)
# Performance for train
y_pred = clf_xgb.predict(X_test)
auc_t = roc_auc_score(y_test, y_pred)
print("AUC performance for test : ", auc_t)
# Calc bal_accuracy, recall, and average positive prediction score
recall_t = recall_score(y_test, y_pred)
print("Recall performance for test : ", recall_t)
f1_t = f1_score(y_test, y_pred)
print("F1 performance for test : ", f1_t)
prcsn_t = precision_score(y_test, y_pred,labels=np.unique(y_pred))
print("Precision performance for test : ", prcsn_t)
kp_t = cohen_kappa_score(y_test, y_pred)
print("Cohen Kappa for test : ", kp_t)
AUC performance for train : 0.7268423776363454
Recall performance for train : 0.7471832072850748
F1 performance for train : 0.7892076948157809
Precision performance for train : 0.8362411470029366
AUC performance for test : 0.6110343978606433
Recall performance for test : 0.6715563506261181
F1 performance for test : 0.7101778282255014
Precision performance for test : 0.753512645523886
Cohen Kappa for test : 0.21011514238033613
from sklearn.model_selection import GridSearchCV # cross validation and tuning
from sklearn.model_selection import RepeatedStratifiedKFold
cv = RepeatedStratifiedKFold(n_splits=10, n_repeats=3, random_state=1)
## ROUND 0
param_grid = {
'scale_pos_weight': [weight]
}
## NOTE: To speed up cross validiation, and to further prevent overfitting
## we are only using a random subset of the data (90%) and are only
## using a random subset of the features (columns) (50%) per tree.
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optimal_params_0 = GridSearchCV(
estimator=xgb.XGBClassifier(objective='binary:logistic',
seed=42,
subsample=0.9,
colsample_bytree=0.5),
param_grid=param_grid,
scoring='roc_auc', ## see https://scikit-learn.org/stable/modules/model_evaluation.html#scori
ng-parameter
verbose=0, # NOTE: If you want to see what Grid Search is doing, set verbose=2
n_jobs = -1,
cv = cv
)
optimal_params_0.fit(X_train,
y_train,
early_stopping_rounds=10,
eval_metric=['auc'],
eval_set=[(X_test, y_test)],
verbose=False)
print(optimal_params_0.best_params_)
{'scale_pos_weight': 0.4955790381712314}
# Performance for train
train_y_pred = optimal_params_0.predict(X_train)
auc = roc_auc_score(y_train, train_y_pred)
recall = recall_score(y_train, train_y_pred)
print("AUC for train : ", auc)
print("Recall for train : ", recall)
AUC for train : 0.6834020319039793
Recall for train : 0.7076709368729742
plot_confusion_matrix(optimal_params_0,
X_test,
y_test,
values_format='d',
display_labels=["No Treatment", "Treatment"])
<sklearn.metrics._plot.confusion_matrix.ConfusionMatrixDisplay at 0x1799dd47fa0>
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# Performance for train
train_y_pred = optimal_params_0.predict(X_train)
auc = roc_auc_score(y_train, train_y_pred)
print("AUC performance for train : ", auc)
# Calc bal_accuracy, recall, and average positive prediction score
recall = recall_score(y_train, train_y_pred)
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print("Recall performance for train : ", recall)
f1 = f1_score(y_train, train_y_pred)
print("F1 performance for train : ", f1)
prcsn = precision_score(y_train, train_y_pred,labels=np.unique(train_y_pred))
print("Precision performance for train : ", prcsn)
# Performance for train
y_pred = optimal_params_0.predict(X_test)
auc_t = roc_auc_score(y_test, y_pred)
print("AUC performance for test : ", auc_t)
# Calc bal_accuracy, recall, and average positive prediction score
recall_t = recall_score(y_test, y_pred)
print("Recall performance for test : ", recall_t)
f1_t = f1_score(y_test, y_pred)
print("F1 performance for test : ", f1_t)
prcsn_t = precision_score(y_test, y_pred,labels=np.unique(y_pred))
print("Precision performance for test : ", prcsn_t)
AUC performance for train : 0.6834020319039793
Recall performance for train : 0.7076709368729742
F1 performance for train : 0.7538018906699548
Precision performance for train : 0.8063665142455153
AUC performance for test : 0.5978129739102193
Recall performance for test : 0.643649373881932
F1 performance for test : 0.6911256242796773
Precision performance for test : 0.7461634176690171
# Use recommended XGboost approach or tune for best performance metric.
weight = optimal_params_0.best_params_['scale_pos_weight']
## ROUND 1
n_estimators = [20,50,100, 200,300,400,500, 600, 700, 800, 900]
learning_rate = [0.0001, 0.001, 0.01, 0.1, 0.2]
scale_pos_weight = [weight]
param_grid_1 = dict(scale_pos_weight=scale_pos_weight,
learning_rate=learning_rate,
n_estimators=n_estimators)
cv = RepeatedStratifiedKFold(n_splits=10, n_repeats=3, random_state=1)
optimal_params_1 = GridSearchCV(
estimator=xgb.XGBClassifier(objective='binary:logistic',
seed=42,
subsample=0.9,
colsample_bytree=0.5),
param_grid=param_grid_1,
scoring='roc_auc', ## see https://scikit-learn.org/stable/modules/model_evaluation.html#scori
ng-parameter
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verbose=0, # NOTE: If you want to see what Grid Search is doing, set verbose=2
n_jobs = -1,
cv = cv
)
optimal_params_1.fit(X_train,
y_train,
early_stopping_rounds=10,
eval_metric=['auc'],
eval_set=[(X_test, y_test)],
verbose=False)
print(optimal_params_1.best_params_)
{'learning_rate': 0.01, 'n_estimators': 200, 'scale_pos_weight': 0.4955790381712314}
# summarize results
print("Best: %f using %s" % (optimal_params_1.best_score_, optimal_params_1.best_params_))
means = optimal_params_1.cv_results_['mean_test_score']
stds = optimal_params_1.cv_results_['std_test_score']
params = optimal_params_1.cv_results_['params']
for mean, stdev, param in zip(means, stds, params):
print("%f (%f) with: %r" % (mean, stdev, param))
# Performance for train
train_y_pred = optimal_params_1.predict(X_train)
auc = roc_auc_score(y_train, train_y_pred)
print("Performance for train : ", auc)
# Performance for test
y_pred_rd1 = optimal_params_1.predict(X_test)
auc_t_rd1 = roc_auc_score(y_test, y_pred_rd1)
print("AUC performance for test : ", auc_t_rd1)
# Calc bal_accuracy, recall, and average positive prediction score
recall_t_rd1 = recall_score(y_test, y_pred_rd1)
print("Recall performance for test : ", recall_t_rd1)
aps_t_rd1 = average_precision_score(y_test, y_pred)
print("APS performance for test: ", aps_t_rd1)
f1_t_rd1 = f1_score(y_test, y_pred_rd1)
print("F1 performance for test : ", f1_t_rd1)
prcsn_t_rd1 = precision_score(y_test, y_pred_rd1,labels=np.unique(y_pred_rd1))
print("Precision performance for test : ", prcsn_t_rd1)
accry_t = accuracy_score(y_test, y_pred_rd1)
print("Accuracy performance for test : ", accry_t)
Performance for train : 0.6850635083482383
AUC performance for test : 0.6114555640824836
Recall performance for test : 0.6826475849731664
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APS performance for test: 0.7196331537267628
F1 performance for test : 0.7158131682611143
Precision performance for test : 0.7523659305993691
Accuracy performance for test : 0.6359048305695746
learning_rate = optimal_params_1.best_params_['learning_rate']
n_estimators = optimal_params_1.best_params_['n_estimators']
## ROUND 2
from sklearn.model_selection import RepeatedStratifiedKFold
param_grid_2 = {
'max_depth': [1,2,3,4,5,6,7,8,9,10,11,12,13,14],
'min_child_weight': [1,2,3,4,5,6,7,8,9,10,11,12,13,14],
'scale_pos_weight': [weight],
'learning_rate':[learning_rate],
'n_estimators':[n_estimators]
}
cv = RepeatedStratifiedKFold(n_splits=10, n_repeats=3, random_state=1)
optimal_params_2 = GridSearchCV(
estimator=xgb.XGBClassifier(objective='binary:logistic',
seed=42,
subsample=0.9,
colsample_bytree=0.5),
param_grid=param_grid_2,
scoring='roc_auc', ## see https://scikit-learn.org/stable/modules/model_evaluation.html#scori
ng-parameter
verbose=3, # NOTE: If you want to see what Grid Search is doing, set verbose=2
n_jobs = -1,
cv = cv
)
optimal_params_2.fit(X_train,
y_train,
early_stopping_rounds=10,
eval_metric=['auc'],
eval_set=[(X_test, y_test)],
verbose=False)
print(optimal_params_2.best_params_)
{'learning_rate': 0.01, 'max_depth': 12, 'min_child_weight': 10, 'n_estimators': 200, 'scale_pos_weig
ht': 0.4955790381712314}
# Performance for train
train_y_pred = optimal_params_2.predict(X_train)
auc = roc_auc_score(y_train, train_y_pred)
print("Performance for train : ", auc)
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# Performance for test
y_pred_rd2 = optimal_params_2.predict(X_test)
auc_t_rd2 = roc_auc_score(y_test, y_pred_rd2)
print("AUC performance for test : ", auc_t_rd2)
aps_t_rd2 = average_precision_score(y_test, y_pred_rd2)
print("APS performance for test: ", aps_t_rd2)
# Calc bal_accuracy, recall, and average positive prediction score
recall_t_rd2 = recall_score(y_test, y_pred_rd2)
print("Recall performance for test : ", recall_t_rd2)
f1_t_rd2 = f1_score(y_test, y_pred_rd2)
print("F1 performance for test : ", f1_t_rd2)
prcsn_t_rd2 = precision_score(y_test, y_pred_rd2,labels=np.unique(y_pred_rd2))
print("Precision performance for test : ", prcsn_t_rd2)
accry_t = accuracy_score(y_test, y_pred_rd2)
print("Accuracy performance for test : ", accry_t)
Performance for train : 0.7176366178513388
AUC performance for test : 0.618159650285361
APS performance for test: 0.7306195103281976
Recall performance for test : 0.6726296958855098
F1 performance for test : 0.7133371276797571
Precision performance for test : 0.7592891760904685
Accuracy performance for test : 0.6368661379476087
min_child_weight = optimal_params_2.best_params_['min_child_weight']
max_depth = optimal_params_2.best_params_['max_depth']
## ROUND 3
param_grid_3 = {
'max_depth': [max_depth],
'min_child_weight': [min_child_weight],
'scale_pos_weight': [weight],
'learning_rate':[learning_rate],
'n_estimators':[n_estimators],
'gamma': [0,0.001,0.002,0.01,0.1,0.2,0.3,0.4,0.5]
}
cv = RepeatedStratifiedKFold(n_splits=10, n_repeats=3, random_state=1)
optimal_params_3 = GridSearchCV(
estimator=xgb.XGBClassifier(objective='binary:logistic',
seed=42,
subsample=0.9,
colsample_bytree=0.5),
param_grid=param_grid_3,
scoring='roc_auc', ## see https://scikit-learn.org/stable/modules/model_evaluation.html#scori
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ng-parameter
verbose=0, # NOTE: If you want to see what Grid Search is doing, set verbose=2
n_jobs = -1,
cv = cv
)
optimal_params_3.fit(X_train,
y_train,
early_stopping_rounds=10,
eval_metric=['auc'],
eval_set=[(X_test, y_test)],
verbose=False)
print(optimal_params_3.best_params_)
{'gamma': 0.01, 'learning_rate': 0.01, 'max_depth': 12, 'min_child_weight': 10, 'n_estimators': 200, 's
cale_pos_weight': 0.4955790381712314}
# Performance for train
train_y_pred = optimal_params_3.predict(X_train)
auc = roc_auc_score(y_train, train_y_pred)
print("Performance for train : ", auc)
# Performance for test
y_pred_rd3 = optimal_params_3.predict(X_test)
auc_t_rd3 = roc_auc_score(y_test, y_pred_rd3)
print("AUC performance for test : ", auc_t_rd3)
# average precision score
aps_t_rd3 = average_precision_score(y_test, y_pred_rd3)
print("APS performance for test: ", aps_t_rd3)
# Calc bal_accuracy, recall, and average positive prediction score
recall_t_rd3 = recall_score(y_test, y_pred_rd3)
print("Recall performance for test : ", recall_t_rd3)
f1_t_rd3 = f1_score(y_test, y_pred_rd3)
print("F1 performance for test : ", f1_t_rd3)
prcsn_t_rd3 = precision_score(y_test, y_pred_rd3,labels=np.unique(y_pred_rd3))
print("Precision performance for test : ", prcsn_t_rd3)
accry_t = accuracy_score(y_test, y_pred_rd3)
print("Accuracy performance for test : ", accry_t)
Performance for train : 0.7176366178513388
AUC performance for test : 0.6183385411619263
APS performance for test: 0.7307162431227368
Recall performance for test : 0.6729874776386404
F1 performance for test : 0.7135811836115326
Precision performance for test : 0.7593863544610416
Accuracy performance for test : 0.6371064647921173
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# set n_estimaters according to round 3
gamma = optimal_params_3.best_params_['gamma']
## ROUND 4
param_grid_4 = {
'max_depth': [max_depth],
'min_child_weight': [min_child_weight],
'scale_pos_weight': [weight],
'learning_rate':[learning_rate],
'n_estimators':[n_estimators],
'gamma': [gamma],
'reg_lambda':[1,2,3,4,5,10,50],
'reg_alpha':[1,2,3,4,5,10,50]
}
cv = RepeatedStratifiedKFold(n_splits=10, n_repeats=3, random_state=1)
optimal_params_4 = GridSearchCV(
estimator=xgb.XGBClassifier(objective='binary:logistic',
seed=42,
subsample=0.9,
colsample_bytree=0.5),
param_grid=param_grid_4,
scoring='roc_auc', ## see https://scikit-learn.org/stable/modules/model_evaluation.html#scori
ng-parameter
verbose=0, # NOTE: If you want to see what Grid Search is doing, set verbose=2
n_jobs = -1,
cv = cv
)
optimal_params_4.fit(X_train,
y_train,
early_stopping_rounds=10,
eval_metric=['auc'],
eval_set=[(X_test, y_test)],
verbose=False)
print(optimal_params_4.best_params_)
{'gamma': 0.01, 'learning_rate': 0.01, 'max_depth': 12, 'min_child_weight': 10, 'n_estimators': 200, 'r
eg_alpha': 1, 'reg_lambda': 3, 'scale_pos_weight': 0.4955790381712314}
# Performance for train
train_y_pred = optimal_params_4.predict(X_train)
auc = roc_auc_score(y_train, train_y_pred)
print("Performance for train : ", auc)
# Performance for test
y_pred_rd4 = optimal_params_4.predict(X_test)
auc_t_rd4 = roc_auc_score(y_test, y_pred_rd4)
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print("AUC performance for test : ", auc_t_rd4)
# Calc bal_accuracy, recall, and average positive prediction score
recall_t_rd4 = recall_score(y_test, y_pred_rd4)
print("Recall performance for test : ", recall_t_rd4)
# average precision score
aps_t_rd4 = average_precision_score(y_test, y_pred_rd4)
print("APS performance for test: ", aps_t_rd4)
f1_t_rd4 = f1_score(y_test, y_pred_rd4)
print("F1 performance for test : ", f1_t_rd4)
prcsn_t_rd4 = precision_score(y_test, y_pred_rd4,labels=np.unique(y_pred_rd4))
print("Precision performance for test : ", prcsn_t_rd4)
accry_t = accuracy_score(y_test, y_pred_rd4)
print("Accuracy performance for test : ", accry_t)
Performance for train : 0.6860186303260307
AUC performance for test : 0.6065291241156949
Recall performance for test : 0.6654740608228981
APS performance for test: 0.7242139745672891
F1 performance for test : 0.7054807509956381
Precision performance for test : 0.7506053268765133
Accuracy performance for test : 0.6267724104782504
reg_lambda = optimal_params_4.best_params_['reg_lambda']
reg_alpha = optimal_params_4.best_params_['reg_alpha']
## ROUND 5
param_grid_5 = {
'max_depth': [max_depth],
'min_child_weight': [min_child_weight],
'scale_pos_weight': [weight],
'learning_rate':[learning_rate],
'n_estimators':[n_estimators],
'gamma': [gamma],
'reg_lambda':[reg_lambda],
'reg_alpha':[reg_alpha],
'subsample':[0.3,0.5,0.7,0.9],
'colsample_bytree':[0.3,0.5,0.7,0.9]
}
cv = RepeatedStratifiedKFold(n_splits=10, n_repeats=3, random_state=1)
optimal_params_5 = GridSearchCV(
estimator=xgb.XGBClassifier(objective='binary:logistic',
seed=42
),
param_grid=param_grid_5,
scoring='roc_auc', ## see https://scikit-learn.org/stable/modules/model_evaluation.html#scori
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ng-parameter
verbose=0, # NOTE: If you want to see what Grid Search is doing, set verbose=2
n_jobs = -1,
cv = cv
)
optimal_params_5.fit(X_train,
y_train,
early_stopping_rounds=10,
eval_metric=['auc'],
eval_set=[(X_test, y_test)],
verbose=False)
print(optimal_params_5.best_params_)
{'colsample_bytree': 0.5, 'gamma': 0.01, 'learning_rate': 0.01, 'max_depth': 12, 'min_child_weight': 1
0, 'n_estimators': 200, 'reg_alpha': 1, 'reg_lambda': 3, 'scale_pos_weight': 0.4955790381712314, 'sub
sample': 0.9}
# Performance for train
train_y_pred = optimal_params_5.predict(X_train)
auc = roc_auc_score(y_train, train_y_pred)
print("Performance for train : ", auc)
# Performance for test
y_pred_rd5 = optimal_params_5.predict(X_test)
auc_t_rd5 = roc_auc_score(y_test, y_pred_rd5)
print("AUC performance for test : ", auc_t_rd5)
# average precision score
aps_t_rd5 = average_precision_score(y_test, y_pred_rd5)
print("APS performance for test: ", aps_t_rd5)
# Calc bal_accuracy, recall, and average positive prediction score
recall_t_rd5 = recall_score(y_test, y_pred_rd5)
print("Recall performance for test : ", recall_t_rd5)
f1_t_rd5 = f1_score(y_test, y_pred_rd5)
print("F1 performance for test : ", f1_t_rd5)
prcsn_t_rd5 = precision_score(y_test, y_pred_rd5,labels=np.unique(y_pred_rd5))
print("Precision performance for test : ", prcsn_t_rd5)
accry_t = accuracy_score(y_test, y_pred_rd5)
print("Accuracy performance for test : ", accry_t)
Performance for train : 0.6860186303260307
AUC performance for test : 0.6065291241156949
APS performance for test: 0.7242139745672891
Recall performance for test : 0.6654740608228981
F1 performance for test : 0.7054807509956381
Precision performance for test : 0.7506053268765133
Accuracy performance for test : 0.6267724104782504
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subsample = optimal_params_5.best_params_['subsample']
colsample_bytree = optimal_params_5.best_params_['colsample_bytree']
## ROUND 6
param_grid_6 = {
'max_depth': [max_depth],
'min_child_weight': [min_child_weight],
'scale_pos_weight': [weight],
'learning_rate':[learning_rate],
'n_estimators':[n_estimators],
'gamma': [gamma],
'reg_lambda':[reg_lambda],
'reg_alpha':[reg_alpha],
'subsample':[subsample],
'colsample_bytree':[colsample_bytree]
}
cv = RepeatedStratifiedKFold(n_splits=10, n_repeats=3, random_state=1)
optimal_params_6 = GridSearchCV(
estimator=xgb.XGBClassifier(objective='binary:logistic',
seed=42),
param_grid=param_grid_6,
scoring='roc_auc', ## see https://scikit-learn.org/stable/modules/model_evaluation.html#scori
ng-parameter
verbose=0, # NOTE: If you want to see what Grid Search is doing, set verbose=2
n_jobs = -1,
cv = cv
)
optimal_params_6.fit(X_train,
y_train,
early_stopping_rounds=10,
eval_metric=['auc'],
eval_set=[(X_test, y_test)],
verbose=False)
print(optimal_params_6.best_params_)
{'colsample_bytree': 0.5, 'gamma': 0.01, 'learning_rate': 0.01, 'max_depth': 12, 'min_child_weight': 1
0, 'n_estimators': 200, 'reg_alpha': 1, 'reg_lambda': 3, 'scale_pos_weight': 0.4955790381712314, 'sub
sample': 0.9}
print(f'Best: {optimal_params_6.best_score_} using {optimal_params_6.best_params_}','\n')
Best: 0.6860864943064999 using {'colsample_bytree': 0.5, 'gamma': 0.01, 'learning_rate': 0.01, 'max
_depth': 12, 'min_child_weight': 10, 'n_estimators': 200, 'reg_alpha': 1, 'reg_lambda': 3, 'scale_pos_
weight': 0.4955790381712314, 'subsample': 0.9}
from sklearn.model_selection import cross_validate
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xgbcl = optimal_params_6.best_estimator_
kfold = RepeatedStratifiedKFold(n_splits=10, n_repeats=3, random_state=1)
#refit the model on k-folds to get stable avg error metrics
scores = cross_validate(estimator=xgbcl, X=X_train, y=y_train, cv=kfold, n_jobs=-1,
scoring=['accuracy', 'roc_auc','average_precision','precision', 'recall', 'f1','neg_log_loss'])
print('Training 5-fold Cross Validation Results:\n')
print('AUC: ', scores['test_roc_auc'].mean())
print('Average precision: ', scores['test_average_precision'].mean())
print('Accuracy: ', scores['test_accuracy'].mean())
print('Precision: ', scores['test_precision'].mean())
print('Recall: ', scores['test_recall'].mean())
print('F1: ', scores['test_f1'].mean())
print('Neg.LogLoss: ', scores['test_neg_log_loss'].mean(), '\n')
Training 5-fold Cross Validation Results:
AUC: 0.6876457369330226
Average precision: 0.7995369612229754
Accuracy: 0.6535853497120976
Precision: 0.763820977300308
Recall: 0.6962997945567067
F1: 0.7284155332975544
Neg.LogLoss: -0.6369035750460006
AUC: 0.6921795663616259 Accuracy: 0.7015148941290553 Precision: 0.7124730885535536 Recall:
0.926738078882592 F1: 0.8055823014055182 Neg.LogLoss: -0.579314435521734

import sklearn.metrics as metrics
#Fit the final model
xgbcl.fit(X_train, y_train)
#Generate predictions against our training and test data
pred_train = xgbcl.predict(X_train)
proba_train = xgbcl.predict_proba(X_train)
pred_test = xgbcl.predict(X_test)
proba_test = xgbcl.predict_proba(X_test)
# Print model report
print("Classification report (Test): \n")
print(metrics.classification_report(y_test, pred_test))
print("Confusion matrix (Test): \n")
print(metrics.confusion_matrix(y_test, pred_test)/len(y_test))
print ('\nTrain Accuracy:', metrics.accuracy_score(y_train, pred_train))
print ('Test Accuracy:', metrics.accuracy_score(y_test, pred_test))
print ('\nTrain AUC:', metrics.roc_auc_score(y_train, proba_train[:,1]))
print ('Test AUC:', metrics.roc_auc_score(y_test, proba_test[:,1]))
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# calculate the fpr and tpr for all thresholds of the classification
train_fpr, train_tpr, train_threshold = metrics.roc_curve(y_train, proba_train[:,1])
test_fpr, test_tpr, test_threshold = metrics.roc_curve(y_test, proba_test[:,1])
train_roc_auc = metrics.auc(train_fpr, train_tpr)
test_roc_auc = metrics.auc(test_fpr, test_tpr)
import matplotlib.pyplot as plt
fig, ax = plt.subplots(figsize=[7,5])
plt.title('Receiver Operating Characteristic')
plt.plot(train_fpr, train_tpr, 'b', label = 'Train AUC = %0.2f' % train_roc_auc)
plt.plot(test_fpr, test_tpr, 'g', label = 'Test AUC = %0.2f' % test_roc_auc)
plt.legend(loc = 'lower right')
plt.plot([0, 1], [0, 1],'r--')
plt.xlim([0, 1])
plt.ylim([0, 1])
plt.ylabel('True Positive Rate')
plt.xlabel('False Positive Rate')
plt.show()
# plot feature importance
xgb.plot_importance(xgbcl, importance_type='gain');
Classification report (Test):
precision recall f1-score support
0.0
1.0

0.44
0.75

accuracy
macro avg
weighted avg

0.55
0.67

0.60
0.65

0.49 1366
0.71 2795

0.63 4161
0.61 0.60 4161
0.63 0.63 4161

Confusion matrix (Test):
[[0.17976448 0.14852199]
[0.2247056 0.44700793]]
Train Accuracy: 0.6966731898238747
Test Accuracy: 0.6267724104782504
Train AUC: 0.755213509518965
Test AUC: 0.6567936626008062
png

png
png

png
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from sklearn.calibration import CalibratedClassifierCV
fig, ax = plt.subplots(1, figsize=(12, 6))
# Create an uncorrected classifier.
clf = xgc
clf.fit(X_train, y_train)
y_test_predict_proba = clf.predict_proba(X_test)[:, 1]
fraction_of_positives, mean_predicted_value = calibration_curve(y_test, y_test_predict_proba, n_b
ins=10)
plt.plot(mean_predicted_value, fraction_of_positives, 's-', color='red', label='Uncalibrated')
# Create a corrected classifier.
clf_sigmoid = CalibratedClassifierCV(clf, cv=3, method='sigmoid')
clf_sigmoid.fit(X_train, y_train)
y_test_predict_proba = clf_sigmoid.predict_proba(X_test)[:, 1]
fraction_of_positives, mean_predicted_value = calibration_curve(y_test, y_test_predict_proba, n_b
ins=10)
plt.plot(mean_predicted_value, fraction_of_positives, 's-', label='Calibrated (Platt)')
plt.plot([0, 1], [0, 1], '--', color='gray')
# Create a corrected classifier.
clf_sigmoid_tune = CalibratedClassifierCV(xgbcl, cv=3, method='sigmoid')
clf_sigmoid_tune.fit(X_train, y_train)
y_test_predict_proba = clf_sigmoid_tune.predict_proba(X_test)[:, 1]
fraction_of_positives, mean_predicted_value = calibration_curve(y_test, y_test_predict_proba, n_b
ins=10)
plt.plot(mean_predicted_value, fraction_of_positives, 's-', label='Calibrated (Platt), After tune')
plt.plot([0, 1], [0, 1], '--', color='green')
sns.despine(left=True, bottom=True)
plt.gca().xaxis.set_ticks_position('none')
plt.gca().yaxis.set_ticks_position('none')
plt.gca().legend()
plt.title("$XGClassifier$ Sample Calibration Curve", fontsize=20); pass
png

png
import sklearn.metrics as metrics
#Fit the final model
clf_sigmoid_tune.fit(X_train, y_train)
#Generate predictions against our training and test data
pred_train = clf_sigmoid_tune.predict(X_train)
proba_train = clf_sigmoid_tune.predict_proba(X_train)
pred_test = clf_sigmoid_tune.predict(X_test)
proba_test = clf_sigmoid_tune.predict_proba(X_test)
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# Print model report
print("Classification report (Test): \n")
print(metrics.classification_report(y_test, pred_test))
print("Confusion matrix (Test): \n")
print(metrics.confusion_matrix(y_test, pred_test)/len(y_test))
print ('\nTrain Accuracy:', metrics.accuracy_score(y_train, pred_train))
print ('Test Accuracy:', metrics.accuracy_score(y_test, pred_test))
print ('\nTrain AUC:', metrics.roc_auc_score(y_train, proba_train[:,1]))
print ('Test AUC:', metrics.roc_auc_score(y_test, proba_test[:,1]))
print ('\nTrain PR-AUC:', metrics.average_precision_score(y_train, proba_train[:,1]))
print ('Test PR-AUC:', metrics.average_precision_score(y_test, proba_test[:,1]))
# calculate the fpr and tpr for all thresholds of the classification
train_fpr, train_tpr, train_threshold = metrics.roc_curve(y_train, proba_train[:,1])
test_fpr, test_tpr, test_threshold = metrics.roc_curve(y_test, proba_test[:,1])
train_roc_auc = metrics.auc(train_fpr, train_tpr)
test_roc_auc = metrics.auc(test_fpr, test_tpr)
import matplotlib.pyplot as plt
fig, ax = plt.subplots(figsize=[7,5])
plt.title('Receiver Operating Characteristic')
plt.plot(train_fpr, train_tpr, 'b', label = 'Train AUC = %0.2f' % train_roc_auc)
plt.plot(test_fpr, test_tpr, 'g', label = 'Test AUC = %0.2f' % test_roc_auc)
plt.legend(loc = 'lower right')
plt.plot([0, 1], [0, 1],'r--')
plt.xlim([0, 1])
plt.ylim([0, 1])
plt.ylabel('True Positive Rate')
plt.xlabel('False Positive Rate')
plt.show()
# plot feature importance
xgb.plot_importance(xgbcl, importance_type='gain');
Classification report (Test):
precision recall f1-score support
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Confusion matrix (Test):
[[0.0752223 0.25306417]
[0.05118962 0.62052391]]
Train Accuracy: 0.7289113193943764
Test Accuracy: 0.695746214852199
Train AUC: 0.7814297155324872
Test AUC: 0.6598860127240391
Train PR-AUC: 0.8725053236929292
Test PR-AUC: 0.7798344142467664
# predicted probabilities using tuning and calibration curve
final_model = clf_sigmoid_tune.fit(X_train, np.ravel(y_train))
predictions = final_model.predict(X_test)
preds = final_model.predict_proba(X_test)
# Create a dataframe for the probabilities of treatment
preds_df = pd.DataFrame(preds[:,1], columns = ['prob_treatment'])
print("Accuracy Score Before and After Thresholding: {}, {}".format(accuracy_score(y_test, predictio
ns), accuracy_score(y_test, roc_predictions)))
print("Precision Score Before and After Thresholding: {}, {}".format(precision_score(y_test, predictio
ns), precision_score(y_test, roc_predictions)))
print("Recall Score Before and After Thresholding: {}, {}".format(recall_score(y_test, predictions), re
call_score(y_test, roc_predictions)))
print("F1 Score Before and After Thresholding: {}, {}".format(f1_score(y_test, predictions), f1_score(
y_test, roc_predictions)))
print("Roc Score Before and After Thresholding: {}, {}".format(roc_auc_score(y_test, predictions), ro
c_auc_score(y_test, roc_predictions)))
Accuracy Score Before and After Thresholding: 0.695746214852199, 0.6534486902186974
Precision Score Before and After Thresholding: 0.7103163686382393, 0.7420393559928443
Recall Score Before and After Thresholding: 0.9237924865831842, 0.7420393559928443
F1 Score Before and After Thresholding: 0.8031104199066873, 0.7420393559928443
Roc Score Before and After Thresholding: 0.5764643252828073, 0.6071104539847092
from sklearn.calibration import CalibratedClassifierCV
fig, ax = plt.subplots(1, figsize=(12, 6))
# Create an uncorrected classifier.
clf = xgbcl
clf.fit(X_train, y_train)
y_test_predict_proba = clf.predict_proba(X_test)[:, 1]
fraction_of_positives, mean_predicted_value = calibration_curve(y_test, y_test_predict_proba, n_b
ins=10)
plt.plot(mean_predicted_value, fraction_of_positives, 's-', color='red', label='Uncalibrated')
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# Create a corrected classifier.
clf_sigmoid = CalibratedClassifierCV(clf, cv=3, method='sigmoid')
clf_sigmoid.fit(X_train, y_train)
y_test_predict_proba = clf_sigmoid.predict_proba(X_test)[:, 1]
fraction_of_positives, mean_predicted_value = calibration_curve(y_test, y_test_predict_proba, n_b
ins=10)
plt.plot(mean_predicted_value, fraction_of_positives, 's-', label='Calibrated (Platt)')
plt.plot([0, 1], [0, 1], '--', color='gray')
# Create a corrected classifier.
clf_sigmoid_tune = CalibratedClassifierCV(optimal_params_6.best_estimator_, cv=3, method='sig
moid')
clf_sigmoid_tune.fit(X_train, y_train)
y_test_predict_proba = clf_sigmoid_tune.predict_proba(X_test)[:, 1]
fraction_of_positives, mean_predicted_value = calibration_curve(y_test, y_test_predict_proba, n_b
ins=10)
plt.plot(mean_predicted_value, fraction_of_positives, 's-', label='Calibrated (Platt), After tune')
plt.plot([0, 1], [0, 1], '--', color='green')
# Create a corrected classifier.
fraction_of_positives, mean_predicted_value = calibration_curve(y_test, roc_predictions, n_bins=1
0)
plt.plot(mean_predicted_value, fraction_of_positives, 's-', label='Calibrated (Platt), After tune & thre
shold')
plt.plot([0, 1], [0, 1], '--', color='yellow')
sns.despine(left=True, bottom=True)
plt.gca().xaxis.set_ticks_position('none')
plt.gca().yaxis.set_ticks_position('none')
plt.gca().legend()
plt.title("$XGClassifier$ Sample Calibration Curve", fontsize=20); pass
png

png
import shap
shap_values_list = []
shap_values_list_1000 = []
for calibrated_classifier in clf_sigmoid_tune.calibrated_classifiers_:
explainer = shap.TreeExplainer(calibrated_classifier.base_estimator)
shap_values = explainer.shap_values(X_train)
shap_values_1000 = explainer.shap_values(X_test[:1000])
shap_values_list_1000.append(shap_values_1000)
shap_values_list.append(shap_values)
shap_values = np.array(shap_values_list).sum(axis=0) / len(shap_values_list)
First summary plot is tune
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# Shap values for positive class
shap.summary_plot(shap_values, X_train, max_display=15, cmap=plt.get_cmap("cool"))
# Shap values for positive class
shap.summary_plot(shap_values, X_train, max_display=15, plot_type="bar", cmap=plt.get_cmap("
cool"))
# Shap values for positive class
shap.summary_plot(shap_values, X_train, max_display=50, plot_type="bar", cmap=plt.get_cmap("
cool"))
shap.dependence_plot("Married", shap_values, X_train.values, feature_names=feature_names,inter
action_index=None, cmap=plt.get_cmap("cool"))
shap.dependence_plot("Age group 66-74", shap_values, X_train.values, feature_names=feature_na
mes,interaction_index=None, cmap=plt.get_cmap("cool"))

shap.dependence_plot("Care fragmentation", shap_values, X_train.values, feature_names=feature_
names,interaction_index=None, cmap=plt.get_cmap("cool"))
shap.dependence_plot("Median income", shap_values, X_train.values, feature_names=feature_nam
es,interaction_index=None, cmap=plt.get_cmap("cool"))
shap.dependence_plot("Life expectancy over 10 years", shap_values, X_train.values, feature_names=
feature_names,interaction_index=None, cmap=plt.get_cmap("cool"))
shap.dependence_plot("Multimorbidity group", shap_values, X_train.values, feature_names=feature
_names,interaction_index=None, cmap=plt.get_cmap("cool"))
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Appendix 7.8 Aim 3 python codes

import pandas as pd
import numpy as np
from scipy.stats import stats, randint
import random
from sklearn.model_selection import GridSearchCV, cross_val_score, learning_curve
from sklearn.model_selection import train_test_split
import xgboost as xgb
from collections import Counter
import itertools
import matplotlib.pyplot as plt
import numpy as np
import seaborn as sns
X_vars = [
"Age at diagnosis",
"Hispanic",
"Metro locality",
"Physical condition total","Mental health condition total",
"A1c screening","Influenza vaccination","Lipid screening",
"SEER Northcentral","SEER Northeast","SEER South","SEER West",
"White race","Black race","Other race",
"Psyhcology visit","Primary Care visit",
"Median income",
"Urologist density","Radiation Oncologist density",
"College education","Less than highschool education",
"PCCI",
"Married","Separated/Divorced/Widowed","Unmarried","Marital status unknown",
"Low-risk prostate cancer",
"Low value care (sum)",
"Conservative management",
"Care fragmentation",
"Diagnostic year 2005",
'Diagnostic year 2006',
'Diagnostic year 2007',
'Diagnostic year 2008',
'Diagnostic year 2009',
'Diagnostic year 2010',
'Diagnostic year 2011',
'Diagnostic year 2012',
'Diagnostic year 2013',
'Diagnostic year 2014'
]
# use the list to select a subset of the original DataFrame
X = dataset[X_vars]

105

y = dataset['notx_12_24maft']
y.head()
0 3404.767935
1 1613.494700
2 54756.131876
3 143.520000
4 3225.969687
Name: notx_12_24maft, dtype: float64
import matplotlib.pyplot as plt
import seaborn as sns; sns.set()
#Organize Data
SR_y = pd.Series(y, name="y (Target Vector Distribution)")
#Plot Data
fig, ax = plt.subplots()
sns.distplot(SR_y, bins=25, color="g", ax=ax)
plt.show()
png

png
#X_train, y_train
XGB regressor with grid search

import numpy as np
import pandas as pd
from sklearn import preprocessing
import xgboost as xgb
from xgboost.sklearn import XGBRegressor
import datetime
from sklearn.model_selection import GridSearchCV
from sklearn.metrics import r2_score
y_train_full = dataset['notx_12_24maft']
x_train_full = dataset.drop(["notx_12_24maft"], axis=1)
y_train_full = np.log1p(y_train_full)
Confirm y_ln distribution

import matplotlib.pyplot as plt
import seaborn as sns; sns.set()
#Organize Data
SR_y_ln = pd.Series(y_train_full, name="y (Target Vector Distribution)")
#Plot Data
fig, ax = plt.subplots()
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sns.distplot(SR_y_ln, bins=25, color="g", ax=ax)
plt.show()
png

png
# Split, check distribution of train/test features
from sklearn.model_selection import train_test_split
X_train, X_test, y_train, y_test = train_test_split(x_train_full, y_train_full, test_size=0.3, random_
state=1)
print(X_train.shape)
print(X_test.shape)
print(y_train.shape)
print(y_test.shape)
(52969, 45)
(22702, 45)
(52969,)
(22702,)
import xgboost as xgb
from sklearn.metrics import r2_score, mean_squared_error, mean_absolute_error
#set cross-validation and defaults
cv=10
seed=33
#
n_estimators = [500,670,675]
learning_rate = [0.008,0.009,0.01]
param_grid_1 = dict(learning_rate=learning_rate,
n_estimators=n_estimators)
xgb_model = XGBRegressor(objective = 'reg:squarederror',
seed=seed)
optimal_params_1 = GridSearchCV(
estimator = xgb_model,
param_grid = param_grid_1,
scoring = 'r2', #R2 tune
#scoring = 'neg_mean_squared_error', #MSE
cv = cv,
n_jobs = -1,
verbose = 1
)
optimal_params_1.fit(X_train,
y_train,
early_stopping_rounds=10,
eval_set=[(X_test, y_test)],
107

verbose=False)
print("Learning rate: ", optimal_params_1.best_params_['learning_rate'])
print("n_estimators: ",optimal_params_1.best_params_['n_estimators'])
Fitting 10 folds for each of 9 candidates, totalling 90 fits
[Parallel(n_jobs=-1)]: Using backend LokyBackend with 12 concurrent workers.
[Parallel(n_jobs=-1)]: Done 26 tasks | elapsed: 3.8min
[Parallel(n_jobs=-1)]: Done 90 out of 90 | elapsed: 10.1min finished
Learning rate: 0.009
n_estimators: 670
# summarize results
print("Best: %f using %s" % (optimal_params_1.best_score_, optimal_params_1.best_params_))
means = optimal_params_1.cv_results_['mean_test_score']
stds = optimal_params_1.cv_results_['std_test_score']
params = optimal_params_1.cv_results_['params']
for mean, stdev, param in zip(means, stds, params):
print("%f (%f) with: %r" % (mean, stdev, param))
Best: 0.344432 using {'learning_rate': 0.009, 'n_estimators': 670}
0.339254 (0.025079) with: {'learning_rate': 0.008, 'n_estimators': 500}
0.344367 (0.024457) with: {'learning_rate': 0.008, 'n_estimators': 670}
0.344394 (0.024453) with: {'learning_rate': 0.008, 'n_estimators': 675}
0.342533 (0.024821) with: {'learning_rate': 0.009, 'n_estimators': 500}
0.344432 (0.024475) with: {'learning_rate': 0.009, 'n_estimators': 670}
0.344430 (0.024477) with: {'learning_rate': 0.009, 'n_estimators': 675}
0.343783 (0.024534) with: {'learning_rate': 0.01, 'n_estimators': 500}
0.344329 (0.024393) with: {'learning_rate': 0.01, 'n_estimators': 670}
0.344329 (0.024393) with: {'learning_rate': 0.01, 'n_estimators': 675}
y_train_pred = optimal_params_1.best_estimator_.predict(X_train)
y_test_pred = optimal_params_1.best_estimator_.predict(X_test)
print('XGBregressor evaluating result:')
print("Train MAE: ", sklearn.metrics.mean_absolute_error(y_train, y_train_pred))
print("Train RMSE: ", np.sqrt(sklearn.metrics.mean_squared_error(y_train, y_train_pred)))
print("Train R2: ", np.sqrt(sklearn.metrics.r2_score(y_train, y_train_pred)))
print("Test MAE: ", sklearn.metrics.mean_absolute_error(y_test, y_test_pred))
print("Test RMSE: ", np.sqrt(sklearn.metrics.mean_squared_error(y_test, y_test_pred)))
print("Test R2: ", np.sqrt(sklearn.metrics.r2_score(y_test, y_test_pred)))
XGBregressor evaluating result:
Train MAE: 1.1343200343381408
Train RMSE: 1.5691095294270383
Train R2: 0.6387264523125636
Test MAE: 1.1727194767606826
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Test RMSE: 1.627370752580571
Test R2: 0.5810544023298005
learning_rate = optimal_params_1.best_params_['learning_rate']
n_estimators = optimal_params_1.best_params_['n_estimators']
param_grid_2 = {'learning_rate':[learning_rate],
'n_estimators':[n_estimators],
'max_depth':[4,5,6],
'min_child_weight':[11,12,13]
}
xgb_model = XGBRegressor(objective = 'reg:squarederror',
seed=seed)
optimal_params_2 = GridSearchCV(
estimator = xgb_model,
param_grid = param_grid_2,
scoring = 'r2',
#scoring = 'neg_mean_absolute_error', #MAE
#scoring = 'neg_mean_squared_error', #MSE
cv = cv,
n_jobs = -1,
verbose = 1
)
optimal_params_2.fit(X_train,
y_train,
early_stopping_rounds=10,
eval_set=[(X_test, y_test)],
verbose=False)
print("max_depth: ", optimal_params_2.best_params_['max_depth'])
print("min_child_weight: ",optimal_params_2.best_params_['min_child_weight'])
Fitting 10 folds for each of 9 candidates, totalling 90 fits
[Parallel(n_jobs=-1)]: Using backend LokyBackend with 12 concurrent workers.
[Parallel(n_jobs=-1)]: Done 26 tasks | elapsed: 2.9min
[Parallel(n_jobs=-1)]: Done 90 out of 90 | elapsed: 9.2min finished
max_depth: 5
min_child_weight: 12
max_depth = optimal_params_2.best_params_['max_depth']
min_child_weight = optimal_params_2.best_params_['min_child_weight']
y_train_pred = optimal_params_2.best_estimator_.predict(X_train)
y_test_pred = optimal_params_2.best_estimator_.predict(X_test)
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print('XGBregressor evaluating result:')
print("Train MAE: ", sklearn.metrics.mean_absolute_error(y_train, y_train_pred))
print("Train RMSE: ", np.sqrt(sklearn.metrics.mean_squared_error(y_train, y_train_pred)))
print("Train R2: ", np.sqrt(sklearn.metrics.r2_score(y_train, y_train_pred)))
print("Test MAE: ", sklearn.metrics.mean_absolute_error(y_test, y_test_pred))
print("Test RMSE: ", np.sqrt(sklearn.metrics.mean_squared_error(y_test, y_test_pred)))
print("Test R2: ", np.sqrt(sklearn.metrics.r2_score(y_test, y_test_pred)))
XGBregressor evaluating result:
Train MAE: 1.1557842730348065
Train RMSE: 1.6082375631598405
Train R2: 0.6148797875288853
Test MAE: 1.1723220292261036
Test RMSE: 1.6260654683448836
Test R2: 0.5819676548322498
# gamma tune
param_grid_3 = {'learning_rate':[learning_rate],
'n_estimators':[n_estimators],
'max_depth':[max_depth],
'min_child_weight':[min_child_weight],
'gamma':[0.003,0.004,0.005,0.006,0.007]
}
xgb_model = XGBRegressor(objective = 'reg:squarederror',
seed=seed)
optimal_params_3 = GridSearchCV(
estimator = xgb_model,
param_grid = param_grid_3,
scoring = 'r2', #MAE
#scoring = 'neg_mean_squared_error', #MSE
cv = cv,
n_jobs = -1,
verbose = 1
)
optimal_params_3.fit(X_train,
y_train,
early_stopping_rounds=10,
eval_set=[(X_test, y_test)],
verbose=False)
print("Gamma: ", optimal_params_3.best_params_['gamma'])
Fitting 10 folds for each of 5 candidates, totalling 50 fits
[Parallel(n_jobs=-1)]: Using backend LokyBackend with 12 concurrent workers.
[Parallel(n_jobs=-1)]: Done 26 tasks | elapsed: 3.5min
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[Parallel(n_jobs=-1)]: Done 50 out of 50 | elapsed: 5.3min finished
Gamma: 0.003
gamma = optimal_params_3.best_params_['gamma']
y_train_pred = optimal_params_3.best_estimator_.predict(X_train)
y_test_pred = optimal_params_3.best_estimator_.predict(X_test)
print('XGBregressor evaluating result:')
print("Train MAE: ", sklearn.metrics.mean_absolute_error(y_train, y_train_pred))
print("Train RMSE: ", np.sqrt(sklearn.metrics.mean_squared_error(y_train, y_train_pred)))
print("Train R2: ", np.sqrt(sklearn.metrics.r2_score(y_train, y_train_pred)))
print("Test MAE: ", sklearn.metrics.mean_absolute_error(y_test, y_test_pred))
print("Test RMSE: ", np.sqrt(sklearn.metrics.mean_squared_error(y_test, y_test_pred)))
print("Test R2: ", np.sqrt(sklearn.metrics.r2_score(y_test, y_test_pred)))
XGBregressor evaluating result:
Train MAE: 1.1557842730348065
Train RMSE: 1.6082375631598405
Train R2: 0.6148797875288853
Test MAE: 1.1723220292261036
Test RMSE: 1.6260654683448836
Test R2: 0.5819676548322498
# max_delta_step
param_grid_4 = {'learning_rate':[learning_rate],
'n_estimators':[n_estimators],
'max_depth':[max_depth],
'min_child_weight':[min_child_weight],
'gamma':[gamma],
'max_delta_step':[10,11,12],
}
xgb_model = XGBRegressor(objective = 'reg:squarederror',
seed=seed)
optimal_params_4 = GridSearchCV(
estimator = xgb_model,
param_grid = param_grid_4,
scoring = 'r2', #MAE
#scoring = 'neg_mean_squared_error', #MSE
cv = cv,
n_jobs = -1,
verbose = 1
)
optimal_params_4.fit(X_train,
y_train,
early_stopping_rounds=10,
111

eval_set=[(X_test, y_test)],
verbose=False)
print("max_delta_step: ", optimal_params_4.best_params_['max_delta_step'])
Fitting 10 folds for each of 5 candidates, totalling 50 fits
[Parallel(n_jobs=-1)]: Using backend LokyBackend with 12 concurrent workers.
[Parallel(n_jobs=-1)]: Done 26 tasks | elapsed: 3.6min
[Parallel(n_jobs=-1)]: Done 50 out of 50 | elapsed: 5.5min finished
max_delta_step: 11
max_delta_step = optimal_params_4.best_params_['max_delta_step']
y_train_pred = optimal_params_4.best_estimator_.predict(X_train)
y_test_pred = optimal_params_4.best_estimator_.predict(X_test)
print('XGBregressor evaluating result:')
print("Train MAE: ", sklearn.metrics.mean_absolute_error(y_train, y_train_pred))
print("Train RMSE: ", np.sqrt(sklearn.metrics.mean_squared_error(y_train, y_train_pred)))
print("Train R2: ", np.sqrt(sklearn.metrics.r2_score(y_train, y_train_pred)))
print("Test MAE: ", sklearn.metrics.mean_absolute_error(y_test, y_test_pred))
print("Test RMSE: ", np.sqrt(sklearn.metrics.mean_squared_error(y_test, y_test_pred)))
print("Test R2: ", np.sqrt(sklearn.metrics.r2_score(y_test, y_test_pred)))
XGBregressor evaluating result:
Train MAE: 1.1557842730348065
Train RMSE: 1.6082375631598405
Train R2: 0.6148797875288853
Test MAE: 1.1723220292261036
Test RMSE: 1.6260654683448836
Test R2: 0.5819676548322498
# reg_lambda, alpha
param_grid_5 = {'learning_rate':[learning_rate],
'n_estimators':[n_estimators],
'max_depth':[max_depth],
'min_child_weight':[min_child_weight],
'gamma':[gamma],
'max_delta_step':[max_delta_step],
'reg_lambda':[1,2,3,4,5],
'reg_alpha':[1,2,3,4,5]
}
xgb_model = XGBRegressor(objective = 'reg:squarederror',
seed=seed)
optimal_params_5 = GridSearchCV(
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estimator = xgb_model,
param_grid = param_grid_5,
scoring = 'r2',
#scoring = 'neg_mean_absolute_error', #MAE
#scoring = 'neg_mean_squared_error', #MSE
cv = cv,
n_jobs = -1,
verbose = 1
)
optimal_params_5.fit(X_train,
y_train,
early_stopping_rounds=10,
eval_set=[(X_test, y_test)],
verbose=False)
print("Reg_lambda: ", optimal_params_5.best_params_['reg_lambda'])
print("Reg_alpha: ", optimal_params_5.best_params_['reg_alpha'])
Fitting 10 folds for each of 25 candidates, totalling 250 fits
[Parallel(n_jobs=-1)]: Using backend LokyBackend with 12 concurrent workers.
[Parallel(n_jobs=-1)]: Done 26 tasks | elapsed: 3.8min
[Parallel(n_jobs=-1)]: Done 176 tasks | elapsed: 18.5min
[Parallel(n_jobs=-1)]: Done 250 out of 250 | elapsed: 25.6min finished
Reg_lambda: 2
Reg_alpha: 1
reg_lambda = optimal_params_5.best_params_['reg_lambda']
reg_alpha = optimal_params_5.best_params_['reg_alpha']
y_train_pred = optimal_params_5.best_estimator_.predict(X_train)
y_test_pred = optimal_params_5.best_estimator_.predict(X_test)
print('XGBregressor evaluating result:')
print("Train MAE: ", sklearn.metrics.mean_absolute_error(y_train, y_train_pred))
print("Train RMSE: ", np.sqrt(sklearn.metrics.mean_squared_error(y_train, y_train_pred)))
print("Train R2: ", np.sqrt(sklearn.metrics.r2_score(y_train, y_train_pred)))
print("Test MAE: ", sklearn.metrics.mean_absolute_error(y_test, y_test_pred))
print("Test RMSE: ", np.sqrt(sklearn.metrics.mean_squared_error(y_test, y_test_pred)))
print("Test R2: ", np.sqrt(sklearn.metrics.r2_score(y_test, y_test_pred)))
XGBregressor evaluating result:
Train MAE: 1.1564939892972832
Train RMSE: 1.6098665862703325
Train R2: 0.613853885972447
Test MAE: 1.1725238251572232
Test RMSE: 1.6260069515321633
Test R2: 0.5820085458766149
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# subsample, colsample_bytree
param_grid_6 = {'learning_rate':[learning_rate],
'n_estimators':[n_estimators],
'max_depth':[max_depth],
'min_child_weight':[min_child_weight],
'gamma':[gamma],
'max_delta_step':[max_delta_step],
'reg_lambda':[reg_lambda],
'reg_alpha':[reg_alpha],
'colsample_bytree':[0.5,0.7,0.9],
'subsample':[0.5,0.7,0.9]
}
xgb_model = XGBRegressor(objective = 'reg:squarederror',
seed=seed)
optimal_params_6 = GridSearchCV(
estimator = xgb_model,
param_grid = param_grid_6,
scoring = 'r2',
#scoring = 'neg_mean_absolute_error', #MAE
#scoring = 'neg_mean_squared_error', #MSE
cv = cv,
n_jobs = -1,
verbose = 1
)
optimal_params_6.fit(X_train,
y_train,
early_stopping_rounds=10,
eval_set=[(X_test, y_test)],
verbose=False)
print("colsample_bytree: ", optimal_params_6.best_params_['colsample_bytree'])
print("subsample: ", optimal_params_6.best_params_['subsample'])
Fitting 10 folds for each of 9 candidates, totalling 90 fits
[Parallel(n_jobs=-1)]: Using backend LokyBackend with 12 concurrent workers.
[Parallel(n_jobs=-1)]: Done 26 tasks | elapsed: 2.6min
[Parallel(n_jobs=-1)]: Done 90 out of 90 | elapsed: 8.2min finished
colsample_bytree: 0.7
subsample: 0.7
colsample_bytree = optimal_params_6.best_params_['colsample_bytree']
subsample = optimal_params_6.best_params_['subsample']
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y_train_pred = optimal_params_6.best_estimator_.predict(X_train)
y_test_pred = optimal_params_6.best_estimator_.predict(X_test)
print('XGBregressor evaluating result:')
print("Train MAE: ", sklearn.metrics.mean_absolute_error(y_train, y_train_pred))
print("Train RMSE: ", np.sqrt(sklearn.metrics.mean_squared_error(y_train, y_train_pred)))
print("Train R2: ", np.sqrt(sklearn.metrics.r2_score(y_train, y_train_pred)))
print("Test MAE: ", sklearn.metrics.mean_absolute_error(y_test, y_test_pred))
print("Test RMSE: ", np.sqrt(sklearn.metrics.mean_squared_error(y_test, y_test_pred)))
print("Test R2: ", np.sqrt(sklearn.metrics.r2_score(y_test, y_test_pred)))
XGBregressor evaluating result:
Train MAE: 1.1572504735959093
Train RMSE: 1.608848084830042
Train R2: 0.6144956247430783
Test MAE: 1.1714188531336023
Test RMSE: 1.6218698997451828
Test R2: 0.5848885253562806
model= XGBRegressor(booster='gbtree',
learning_rate= learning_rate,
reg_alpha=reg_alpha,
colsample_bytree= colsample_bytree,
gamma= gamma,
reg_lambda= reg_lambda,
max_delta_step= max_delta_step,
max_depth= max_depth,
min_child_weight= min_child_weight,
n_estimators= n_estimators,
sampling_method='uniform',
subsample= subsample,
seed=seed)
model.fit(X_train, y_train)
XGBRegressor(base_score=0.5, booster='gbtree', colsample_bylevel=1,
colsample_bynode=1, colsample_bytree=0.7, gamma=0.003, gpu_id=-1,
importance_type='gain', interaction_constraints='',
learning_rate=0.009, max_delta_step=11, max_depth=5,
min_child_weight=12, missing=nan, monotone_constraints='()',
n_estimators=670, n_jobs=0, num_parallel_tree=1, random_state=33,
reg_alpha=1, reg_lambda=2, sampling_method='uniform',
scale_pos_weight=1, seed=33, subsample=0.7, tree_method='exact',
validate_parameters=1, verbosity=None)
variables = [
"Age at diagnosis",
"Hispanic",
"Metro locality",
"Physical condition total","Mental health condition total",
"A1c screening","Influenza vaccination","Lipid screening",
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"SEER Northcentral","SEER Northeast","SEER South","SEER West",
"White race","Black race","Other race",
"Psyhcology visit","Primary Care visit",
"Median income",
"Urologist density","Radiation Oncologist density",
"College education","Less than highschool education",
"PCCI",
"Married","Separated/Divorced/Widowed","Unmarried","Marital status unknown",
"Low-risk prostate cancer",
"Low value care (sum)",
"Conservative management",
"Care fragmentation"
]
import shap
explainer = shap.TreeExplainer(model)
shap_values = explainer.shap_values(X_train)
# Shap values for positive class
shap.summary_plot(shap_values, X_train, max_display=10)
# Shap values for positive class
shap.summary_plot(shap_values, X_train, max_display=10, plot_type="bar", cmap=plt.get_cmap("
cool"))
shap.dependence_plot("Physical condition total", shap_values, X_train, interaction_index = None)
shap.dependence_plot("Care fragmentation", shap_values, X_train, interaction_index = None)
shap.dependence_plot("Low value care (sum)", shap_values, X_train, interaction_index = None)
shap.dependence_plot("Conservative management", shap_values, X_train, interaction_index = None
)
shap.dependence_plot("crfrg_10x", shap_values, X_train, interaction_index = "sum_lowval_12mbef
")
shap.dependence_plot("mm_pcci", shap_values, X_train, interaction_index = "sum_lowval_12mbef
")
shap.dependence_plot("mm_pcci", shap_values, X_train, interaction_index = "crfrg_10x")
shap.dependence_plot("Low value care (sum)", shap_values, X_train, interaction_index = "Physical
condition total")
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